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Thesis Abstract 
Background: The Newfoundland and Labrador (NL) population is enriched for certain 
genetic diseases due to genetic drift and founder effects. Five previous studies have 
examined the amount of genetic disease among children admitted to a single pediatric 
hospital. The frequency of strongly genetic disorders (chromosomal and Mendelian 
disorders) ranged from 4 to -11 %, and all the hospitals served admixed populations. We 
conducted a similar study, hypothesizing that the amount of genetic disease among 
hospitalized NL children might be higher than in the previously published studies. 
Objectives: We determined the genetic content of 4,144 consecutive hospitalizations to 
Newfoundland and Labrador's only pediatric hospital. By reviewing the discharge 
summary, each admission was retrospectively classified into one of 11 genetic content 
groups. We also compared the utilization of hospital resources by children with strongly 
genetic versus minimally genetic conditions. Finally, we determined the appropriateness 
of referrals for genetic services. 
Results: Out of 4,144 children, 8.3% had a strongly genetic disease (342 patients with a 
Mendelian or chromosomal syndrome). Another -25% (1 ,033 patients) had a moderately 
genetic disease and 67% (2,769 cases) were classified as minimally genetic. Children in 
the strongly genetic group had a mean length of stay (8.01d) that was significantly longer 
than the non-genetic group (3.99 d), with more cumulative surgeries and cumulative 
hospital days. Children with single-gene disorders were at risk for prolonged lengths of 
stay (> 7days). Of 3,281 unique admissions, 1 in 4 children with a diagnosis that is an 
indication for genetic consultation failed to be referred. The largest deficit occurred for 
11 
children with mental retardation and for those with birth defects that have a significant 
genetic component. 
Conclusions: The proportion of admitted children with chromosomal and Mendelian 
disorders was comparable to previous studies, so that even though certain genetic 
diseases are overrepresented in NL, this is not reflected among hospitalized children. Our 
dataset may be enriched for children with high heritability multifactorial diseases 
(including diabetes and asthma), but comparison with earlier studies is complicated by 
differences in classification schemes and/or by the fact that the incidence of some of 
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Thesis Overview 
This thesis is presented in five chapters. 
Chapter 1 gives a brief description of the rationale for the study, followed by the study' s 
three research questions and our initial hypotheses. 
Chapter 2 contains the literature review and is divided into three sections. It begins with 
an overview of the genetic basis of human disease. Human diseases can be divided in two 
broad categories: diseases that are completely or nearly completely genetically 
determined versus multifactorial diseases. The former category includes chromosomal 
and Mendelian syndromes, along with the more recently delineated genomic disorders. 
The implications for recurrence risk counseling are also reviewed. The second section 
describes Newfoundland and Labrador's unique population structure from a genetic 
perspective, emphasizing that it is one of the few relatively young founder populations 
that has been recognized in the literature. Founder effect has led to over-representation of 
several Mendelian syndromes which are summarized. The third section reviews the five 
previous single-hospital based studies (published from 1973 to 2004) which examined the 
amount and burden of genetic disease among hospitalized children. 
Chapter 3 contains a description of the study methods. Prior to beginning the main 
project, a validation study was performed. The genetic content of 201 randomly selected 
pediatric hospitalizations from the year 2000 were independently categorized in two 
ways: firstly using the research nurse/discharge summary method (which was later also 
used in the main study) and secondly by a gold standard method, i.e. review of the chart 
XV 
and patient by a medical geneticist. Then the main study methods are described 
including: the study population; the sample size calculation; and the data extraction and 
outcomes. Chapter 3 also presents the methods used for analyzing the data. The analysis 
methods are divided into five sections: analysis of the validation dataset; determination of 
the genetic content of the main dataset (4,144 consecutive hospitalizations to the Janeway 
Hospital from an 14-month period, representing 3,281 unique separations); analysis of 
hospital utilization data; regression analysis to test the hypothesis that the genetic content 
of an admission influences length of stay; and analysis of the genetics referral pattern 
data. 
The results are presented in Chapter 4, following the format laid out in Chapter 3. 
Finally, Chapter 5 contains a discussion of the above results, beginning with the 
validation study followed by those of the main study. Where possible, our results were 
compared with previous pediatric hospitalization studies, all of which used samples 
drawn from admixed populations. This comparison includes reanalyses of data from three 
of earlier studies (Day and Holmes 1973; Hallet al. 1978; McCandless et al. 2004). Some 
of the commonest strongly and moderately genetic diagnoses in our unique admission 
dataset are considered in the context of this province's population structure. Then, we 
discuss hospital utilization data. Because of the strength of our length of stay (LOS) data, 
we used multivariate regression to examine the impact of the genetic content of an 
admission on LOS. The referral rates for medical genetic consultation and referral deficit 
patterns are considered. Finally the strengths and weaknesses of this study are presented. 
XVI 
Co-authorship statement 
1) Design and identification of the research proposal: The research topic was identified 
by Dr. Bridget Fernandez who was also primarily responsible for the study design. 
Along with Dr. Proton Rahman (Professor), she was co-principal investigator of the 
grant that was used to fund the study. Modifications to the study design and analysis 
were suggested by Drs. Proton Rahman (Professor), Brendan Barret (Professor) and 
Patrick Parfrey (Professor) and these were incorporated into the study. 
2) Practical aspects of the research: The validation study involved prospective review 
of 20 1 pediatric admissions and the gold standard assessment (examination of the 
patient and review of the medical chart) was completed by Dr. Bridget Fernandez 
with review of the discharge summaries by Ms. Kathy Whitten (research nurse). The 
patients for the validation study were enrolled by Ms.Barbara Noble (research nurse). 
For the main study, Ms. Kathy Whitten reviewed and categorized 4,144 
hospitalizations and each categorization was then reviewed by Dr. Bridget Fernandez. 
An access database for the study was designed by Mr. Craig Harding. Additional 
database support was provided by Ms. Andrea Kavanagh. All data entry for the study 
was completed by Ms. Kathy Whitten. 
3) Data analysis: Ms. Susan Stuckless (statistician) and Dr. Bridget Fernandez 
completed the data analysis and statistical analysis for this study, with input from Drs. 
Brendan Barrett (Professor), Proton Rahman (Professor) and Patrick Parfrey 
(Professor). 
XVll 
4) Manuscript preparation: Dr. Bridget Fernandez performed the literature review and 
wrote the thesis with revisions made by Drs. Brendan Barrett (Professor), Proton 





lA. Background of study: Newfoundland and Labrador (NL) is recognized as having a 
population that is enriched for certain genetic disorders. The province has a population of 
-509,000, and already has 27 entries in Online Mendelian Inheritance of Man 
(www.ncbi.nlm.nih.gov/omiml) as examples of disorders whose genetic basis was 
significantly elucidated using Newfoundland families.1 The nwnber of entries is 10-fold 
higher than that of the neighboring three provinces (Nova Scotia, New Brunswick and 
Prince Edward Island) when adjusted for population size. 
Previous studies from Mexico and the United States revealed that genetic disease is a 
significant cause of admission to pediatric hospitals (Day et al. 1973; Scriver et al. 1973; 
Hallet al. 1978; Carnevale et al. 1985; McCandless et al. 2004). The economic burden of 
patients with genetic disease was also docwnented. However, these studies were 
performed in large tertiary (and in some cases quaternary) hospitals serving admixed 
metropolitan populations. No such data exists for Newfoundland. Obtaining this data has 
immediate implications for managing the health of NL children and for planning the 
resources needed for health care delivery. Because hospitalization is one of the major 
sequelae of morbidity, we examined over 4,000 consecutive pediatric separations from 
the only tertiary children's hospital in the province (the Janeway Children's Health and 
Rehabilitation Centre). 
1 In the genetic literature, our province's population is commonly referred to as ''the 
Newfoundland population" (for examples see Rahman et al. 2003 1; Mannion 1977; 
Martinet al. 2000; Moore et al. 2008). Through this thesis, the term "Newfoundland 
population" or the abbreviation "NL'' is used. 
2 
lB: Hypothesis: Newfoundland has a unique population structure with recognized 
founder effects. We hypothesized that the amount of genetic disease among hospitalized 
children in this province might be higher than in hospitalized children from admixed 
populations. Furthermore, we suspected that children admitted with genetic diseases are 
under-referred for genetic services and that they collectively utilize more hospital 
resources than children with non-genetic conditions. To answer these questions we 
reviewed and described the genetic content of 4,144 consecutive admissions2 to 
Newfoundland's only tertiary pediatric hospital, the Janeway Children's Health and 
Rehabilitation Centre. 
1 C Research Questions: 
1. What is the burden of genetic disease among hospitalized children m 
Newfoundland? 
2. Do pediatric patients with genetic diseases utilize more hospital resources than 
children with non-genetic conditions? 
3. What is the capture/ referral rate to the provincial medical genetics service for 
patients with strongly genetic diseases? 
lD Relevance and benefits of the study: Our findings will generate a number of 
immediate benefits. We have highlighted the burden that genetic diseases impose on this 
province's pediatric health care system, both in terms of inpatient care and medical 
genetics resources. This information can be used by government officials and hospital 
2 Through this thesis, the terms "admissions to hospital", "separations from hospital" and 
"hospitalizations" are used interchangeably. 
3 
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administrators as they make decisions about allocation of funds and recruiting pediatric 
and medical genetic health care professionals. In addition, we used regression analysis to 
test the hypothesis that the genetic content of a pediatric hospitalization impacts length of 
stay. While we found that the specific admitting diagnosis explained the largest 
proportion of the variance, we determined that children with Mendelian diseases who are 
admitted for any reason are at high risk for prolonged length of stay (> 7 days), and this 
information should be useful for hospital discharge planners. Finally, we estimated the 
proportion of hospitalized children who failed to receive appropriate genetic services ( 1 
in 4). Recognition of referral deficit patterns will allow these to be addressed through 





2A The genetic basis of human disease: When medical geneticists formulate a 
differential diagnosis, two broad disease categories are considered: strongly genetic 
disorders versus weakly genetic/acquired disorders. The strongly genetic group includes 
Mendelian, chromosomal and mitochondrial diseases plus the more recently delineated 
category of genomic disorders. 
Mendelian diseases are those that are largely determined by the presence of a mutation or 
mutations in a single gene. These are further classified into one of three inheritance 
patterns: autosomal dominant; autosomal recessive and X-linked. While we now 
appreciate that the severity of a Mendelian disease may be determined by one or more 
additional genes (genetic modifiers), the presence or absence ofthe disease is determined 
by the genotype at one particular genetic locus. For example, variants in the modifier 
gene CFMJ determine the presence or absence of meconium ileus in infants who carry 
recessive mutations in the CFI'R gene and who have cystic fibrosis (Zielensk.i et al. 
1999). 
Chromosome disorders also belong to the strongly genetic category. These are disorders 
where the phenotypes are largely determined by physical changes in either chromosome 
number (e.g. trisomies, the commonest of which is Down syndrome), chromosome 
structure (e.g. translocations, inversions) or in chromosome origin i.e. uniparental 
disomy, which for example explains some cases of Prader Willi syndrome. 
Mitochondrial diseases are produced either by mutations in the circular mitochondrial 
genome (e.g. Leber Hereditary Optic Neuropathy) or by mutations in nuclear DNA genes 
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that encode proteins that are imported into the mitochondria (e.g. autosomal recessive 
Complex I deficiency) (Harper 2003 1). 
Genomic disorders are a relatively recent addition to the group of strongly genetic 
conditions. Affected individuals are usually "syndromic" looking and/or developmentally 
delayed. These diseases are caused by genomic rearrangements (mostly mediated by non-
allelic homologous recombination) which causes a segment of the genome to be present 
in the "wrong dose" (Stankiewicz and Lupski 2003). These microdeletions and 
microduplications are too small to be identified by routine chromosome analysis. Over 
the past five years, it has become possible to screen the entire human genome for 
imbalances that would have escaped detection on routine karyotype using a DNA chip 
technique called genomic microarray analysis. 
The strongly genetic disorders described above have been categorized as "group 1" 
diagnoses in the study that follows. 
Most common diseases do not follow Mendelian patterns of inheritance, but it has long 
been recognized that many show familial clustering, which in some cases is striking. 
These non-Mendelian common diseases include birth defects like congenital heart disease 
and neural tube defects, as well as chronic diseases (examples include asthma, diabetes, 
hypertension and autism). Various terms are used for these in the literature including 
"multifactorial", "polygenic" and "complex" diseases. In his textbook entitled "Practical 
Genetic Counseling", Peter Harper has written that the most appropriate term for these is 
"multifactorial" because this term recognizes that these diseases are caused by both 
genetic and environmental factors. We believe that most of these conditions are caused 
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by multiple genetic factors ("susceptibility alleles"), each one being of small or moderate 
effect (Harper 20032). 
Type I diabetes (TID) is one of the best understood diseases in this group. At least 20 
different susceptibility loci have been identified, the two most important of which are 
IDDMJ (the HLA locus) and IDDM2 (the insulin gene). Polymorphisms of two particular 
HLA genes (DR and DQ) explain 40-50% of this disease's heritability with a "short 
class" VNTR polymorphism of the insulin gene explaining IO% (Dubois La Forgue et al. 
I997; Noble et al. I996). Sheehy et al. (I989) showed that the HLA DR3/4-DQ2/8 
genotype was present in 2.3% of Colarado newborns, but in> 30% of diabetic children. 
While the population risk of TID is 11300, the risk for newborns with this genotype is 
1120. Although babies with this genotype are in an extreme risk group, the majority will 
not develop TID and because no preventive environmental strategy has been identified, 
multifactorial genetic testing for TID is not being done outside of research protocols. 
In the study which follows, the more strongly heritable multifactorial disorders have been 
classified as either group IIA (for birth defects) or group IliA (for non-congenital 
conditions). See section 3B.3 
2A.l Recurrence Risk Counseling: One of the issues that is addressed as part of a 
medical genetic consultation is the risk that parents of the proband face if they decide to 
have another child. 
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Risk figures for Mendelian disorders are derived from a biologic understanding of the 
genetic etiology of the disease. Parents of a child with an autosomal recessive disorder 
have a 1 in 4 chance of having another affected children. A mother with an autosomal 
dominant disease, like Marfan syndrome, has a 50% chance of passing the condition on 
to a child of either sex and so forth. 
At present, "empiric risk" figures are given for most multifactorial conditions, and 
genetic testing for the presence or absence of particular susceptibility alleles is not used 
to give a more precise risk figure. The term empiric means that observational data has 
been collected about reproductive outcomes for the parents of pro bands with a particular 
condition. Provided that the study has been carefully designed and is unbiased, these 
types of "observed" risk figures are used for genetic counseling, and this practice will 
continue until the genetic basis each of these multifactorial diseases is fully understood. 
Unlike Mendelian risk figures which can be universally applied, empiric risk figures are 
population specific and may be altered by factors like disease severity, the number of 
affected family members or the sex of the affected individual (Harper 20032). 
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2A.2 Estimates of the degree of underlying genetic susceptibility for multifactorial 
diseases: Lambda s and Heritability. Lambda s (A.s) and heritability (h2) provide 
information about whether a disease is likely to have a genetic component, although each 
has limitations. 
Lambdas (A.s) is defined as the prevalence of disease in siblings of the proband divided 
by the population prevalence of the disease. It is a measure of familial aggregation which 
is influenced by both shared genes and shared environment. Nevertheless in his 1990 
landmark paper, Neal Risch suggested AS > 2 as a staring point for separating genetic 
from non-genetic diseases. Later, Lander and Schork (1994) stated that the genetic 
mapping of a complex trait is more likely to succeed if the disease has a high AS (> 1 0) 
versus a low one ( <2). 
The concept of heritability was originally developed to quantify the role of genetic 
differences in determining the variability of quantitative traits, like obesity. In contrast to 
AS which is a measure of familial clustering, heritability is defined as the fraction of the 
total phenotypic variance which is caused by genetic factors. Operationally, heritability is 
estimated from twin studies as 2[rMZ-rDZ], where r is the correlation ofliability derived 
from concordance rates between monozygotic (MZ) and dizygotic (DZ) twin pairs. 
The heritability calculation assumes that the environmental variation between identical 
(MZ) and fraternal (DZ) twins is equal. In reality, there is often less environmental 
variation between MZ than DZ pairs so that the calculation may overestimate the effect 
of heritable factors (Jarvinen and Aho 1994; Hawkes 1997). 
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Our present understanding of the genetics of type I diabetes was summarized above 
(section 2A). This disease has heritability estimates of 0.72-0.74 with a A.s of 15 (Kaprio 
et al. 1992; Kyvik et al. 1995). 
For this study, multifactorial diseases were somewhat arbitrarily divided into two groups 
based on the degree to which the disease is estimated to be genetically determined. The 
more strongly genetic group contained diseases that have either a heritability estimate ~ 
50% or a lamda s ~ 10. See section 3B.3 
2B The Newfoundland Disease Heritage: The Newfoundland population is genetically 
enriched. It is primarily composed of descendants from a small number of Irish and 
Southwest English immigrants who settled in the ''New World" around the mid-1700's. 
Starting from about 20,000 settlers in 1760, the population grew by natural expansion to 
~200,000 in 1890 (Mannion 1977). The current provincial population is approximately 
509,000 with 95% of English or Irish descent (Statistics Canada, 2008). This rate of 
expansion is comparable to that of other "young" genetic isolates including the Central 
Valley Costa Ricans and the Afrikaners of South Africa (Escamilla et al. 1996; Rahman 
et al. 20031). Approximately 60% of the population of Newfoundland resides in 
communities with 2,500 inhabitants or less (Statistics Canada, 2001). 
The following population characteristics have contributed to a high prevalence of certain 
genetic disorders in Newfoundland: 
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2B.l Persistent geographic isolation and homogeneity leading to a high kinship 
coefficient in particular rural communities: The cod fishery was responsible for the 
settlement ofNewfoundland, with most immigrants arriving between the mid-1700's and 
the early 1800's. They came from two main areas: southeast Ireland and southwest 
England. By the 1830's the major migrations had concluded, and the population of 
Newfoundland was- 75,000. From this point onwards, the population grew mainly by 
natural expansion. Several factors contributed to keeping related families together 
including: geographic isolation due to lack of roads connecting costal communities; 
religious segregation; and limited immigration (Mannion 1977; Citizens 1977). 
A study of the degree of relatedness in three representative outports (two on the island 
part of the province and one in Labrador) was published by Bear et al. in 1987. The 
authors found that the overwhelming majority of parents originated from the community 
in which they were raising a family. For example, in the eastern island outport only 7-9% 
of the parents came from outside the study area, as did only 0.03% for the west coast 
outport. 
Bear used the same east and west coast outports to show persistent homogeneity of the 
NL population (Bear et al. 1988). Reconstructed pedigree data was used to calculate the 
homogeneity coefficient of every individual born in these outports. For individuals born 
between 1960-79, the average coefficient was 0. 003 2 and 0. 0171 from the east and west 
outports respectively. These coefficients are consistent with genetic isolation and similar 
to the coefficients seen in the Hutterites and Amish (Bowen, 1985). 
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Since the 1980's and the demise of Newfoundland's inshore fishery, there has been 
significant out-migration from certain outports in the province, with almost no in-
migration into any of these communities. However since Bear' s studies, geographic 
isolation has been reduced by modernizing transportation routes. Martin et al. (2000) 
conducted a more recent study; this group determined the allele frequencies for 12 red 
cell antigens from individuals from ten outports, and compared these with the parental 
English and Irish populations. They confirmed persistent genetic isolation in selected NL 
outports, but also identified heterogeneity in the NL population as a whole. 
2B.2.1 Genetic drift producing high frequencies of certain deleterious disease alleles in 
the NL population - Mendelian disorders: The phenomenon of genetic drift refers to 
the fluctuation in allele frequency due to chance operating in a small gene pool contained 
within a small population. Because of the population's size, random factors (e.g. survival, 
increased fertility) may cause the allele frequency to rise for reasons that have nothing to 
do with the mutation itself; in larger populations such random effects have a tendency to 
average out (Nussbaum et al. 2001 1) . Because of drift, founder populations often have an 
increased incidence of particular rare (often autosomal recessive) diseases. This is the 
case in Newfoundland for a number of usually rare autosomal and X-linked Mendelian 
disorders. Up until the present generation, high sibship sizes also contributed to 
increasing the frequency of particular autosomal dominant diseases. 
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Examples of over-represented single-gene conditions in Newfoundland include: Bardet-
Biedl syndrome (Moore et al. 2005); infantile neuronal ceroid lipofucinosis (Moore et al. 
2008); 1-cell disease (Provincial Medical Genetics Program, Eastern Health - PMGP 
database3) ; Krabbe leukodystrophy (PMGP database); type 1 multiple endocrine 
neoplasia (Olufemi et al. 1998; PMGP database) and arrhythmogenic right ventricular 
dysplasia (Memer et al. 2008; PMGP database). 
The example ofBardet-Biedl syndrome is discussed in more detail below. 
Bardet-Biedl svndrome (BBS): This autosomal recessive disease is a syndromic form of 
retinal dystrophy. Its prevalence in NL is 1:18,000, compared with 1:160,000 in more 
admixed Caucasian populations of northern European ancestory (Moore et al. 2005; 
Woods et al. 1999; Young et al. 1999). For a monogenic disease, BBS is unusually 
genetically heterogenous, with 12 known genes, BBSJ-BBS12 (Ross and Beales 2007). 
Over a 20-year period, a team of Newfoundland investigators assembled a local cohort of 
BBS patients and followed them with serial phenotypic measures (Harnett et al. 1988; 
Green et al. 1989; O'Dea et al. 1996; Moore et al. 2005). Given Newfoundland' s 
population structure, it would have been reasonable to hypothesize that all 46 BBS 
patients in the cohort would link to the same BBS locus, and even that most affected 
individuals would have the same homozygous mutation. An overview of the genetic 
studies on these 46 patients was published by Moore et al. in 2005, and there was an 
3 The Provincial Medical Genetics Program (PMGP) database was created when the 
provincial genetics service was established in 1986. It captures demographic information 
from every individual who has been referred for genetic consultation, including those 
who are waiting for assessment and those who have declined appointments. It contains 
fields for referring diagnosis, fmal diagnoses and genetic test results. 
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unexpected amount of genetic heterogeneity. DNA was available from 40/46 affected 
individuals and at least six BBS loci were implicated. The mutations that were identified 
included: one mutation in the BBSJ gene; two mutations in BBS2; and four mutations in 
BBS6. Another ten patients came from families that linked to either BBS3 or BBS5 (at this 
stage the genes at these loci had not been identified) and four patients from three families 
had been excluded from all the BBS loci that were known at the time (8 loci). Amidst all 
this heterogeneity, there was some degree of founder effect. Eight BBS patients from six 
families had the same homozygous BBSJ mutation (p.M390R) which is a common 
mutation in the European parental population. Another 12 patients had homozygous 
copies of one of two BBS6 mutations; one of these two mutations was present in another 
four compound heterozygous patients. 
The molecular genetics of BBS in Newfoundland taught us an important lesson about 
studying monogenic disorders in this province, i.e. that in spite of the existence of a series 
of genetic isolates which are susceptible to genetic drift and founder effects, one cannot 
assume that any given Mendelian disorder will be genetically homogeneous. In 
retrospect, a clue to BBS 's heterogeneity came from the fact that the cases were not 
localized to a series of neighboring Newfoundland communities. Rather affected 
individuals originated from several geographically separate areas on the island portion of 
the province. One is therefore led to the hypothesis that the province's founders 
introduced at least ten mutant BBS alleles into the population. The frequency of these 
alleles may then have been increased by heterozygote advantage and/or by genetic drift, 
producing a dramatically increased incidence of this usually rare autosomal recessive 
disorder. 
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Unexpected genetic heterogeneity has proven to be the case for another over-represented 
autosomal recessive disorder, infantile neuronal ceroid lipofuscinosis, where 18 NL 
probands segregated eight different mutations in four NCL genes: CLN2, CLN3, CLN5 
and CLN6 (Moore et al. 2008). 
2B.2.2 Genetic drift producing high frequencies of certain deleterious disease alleles in 
the Newfoundland population -Multifactorial diseases: While the value of isolates 
(like parts of NL) for identifying genes of major effect is unquestioned, the contribution 
that these can make towards elucidating the molecular genetics of complex 
(multifactorial) diseases is controversial (Kruglyak 1999; Laitinen 2002; Rahman et al. 
2003 1; Varilo and Peltonen 2004). Extrapolating from the experience with single-gene 
disorders, it has been hypothesized that the molecular genetics of multifactorial diseases 
in isolates will be less complex than in admixed populations, with enrichment of some 
loci and diminution of others. In other words, genetic drift may have led to elevated 
frequencies of susceptibility alleles for particular complex diseases. In some instances, 
this would be expected to increase the occurrence of that disease in the population. In line 
with this theory, an increased incidence of certain complex diseases has been noted in 
Newfoundland, for example: 
1) Psoriasis: there is a 2 to 3-fold increased incidence of psoriasis (approximately 5%) 
compared with most other Caucasian populations (Nail et al. 1999). 
2) Juvenile insulin-dependent diabetes: Newhook et al. (2004) determined that the 
Avalon Peninsula of Newfoundland (which contains - 45% of the province' s children) 
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has the highest reported incidence of type I diabetes worldwide. For the 0-14 year age 
group, over the 4-year period from 1998-2002, the incidence per year was> 40/100,000. 
This is far greater than the incidence in admixed US populations (7-15/100,000) 
(Karvonen et al. 2000), and even exceeds the incidence of juvenile diabetes in other 
recognized founder populations including Sardinia (36.8/1 00,000) and Finland 
(36.5/1 00,000). 
3) Neural tube defects CNTD's): Spina bifida is the paradigm for a multifactorial birth 
defect with a known susceptibility allele (MI'HFR) and a firmly delineated environmental 
risk factor (maternal folate deficiency). Studies in the early 1990's demonstrated that a 
woman's risk for having a child with an NTD could be significantly reduced by 
peri conceptional folic acid supplementation (MRC 1991; Czeizel and Dudas 1992). In 
spite of knowing this, public health campaigns promoting daily use of a folate-containing 
multivitamin for all women of childbearing age (without mandatory food fortification) 
did not appreciably decrease the incidence ofNTD's (Abramsky et al. 1999; Olney and 
Mulinare 2002). In contrast, data from countries with mandatory folate food fortification 
programs have shown a 30-50% decrease in NTD incidence post-fortification (Honein et 
al. 2001; Persad et al. 2002; De Wals et al. 2003). 
A Newfoundland NTD database is housed in the Provincial Medical Genetics Program 
(PMGP). It is updated annually, and multiple sources of ascertainment are used to 
identify all affected liveborns, stillborns, and terminations of pregnancy. Over the 1991-
1996 period (pre-fortification), the incidence of NTD in Newfoundland was 4.67 per 
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1000 live births, and fell to 1.01 during the 1998-2002 post-fortification period (House et 
al. 2006). 
The Newfoundland NTD data along with that of six other Canadian provinces was 
analyzed by De Wals et al. 2007. During the pre-fortification period of Jan 1993-
September 1997, the incidence of NTD in all seven Canadian provinces was 1.58 per 
1,000 births with the incidence in Newfoundland being 4.46. In the post-fortification 
period (April2000-December 2002) the Canadian incidence fell to 0.86 and the incidence 
in Newfoundland fell to 0.75. The rate drop in Newfoundland (3.8) was the highest of the 
seven provinces. 
Improvement in the folate status of pregnant Newfoundland women post-fortification has 
been proven (House et al. 2006; Friel et al. 1995). One could hypothesize that the 
relatively high incidence of NTD's in NL prior to flour fortification was entirely 
attributable to an environmental factor, because the incidence fell to the Canadian 
national average post-fortification. Alternatively, the NL population may have a higher 
frequency of particular NTD susceptibility alleles that interact with maternal folate status 
to produce a child with spina bifida. The latter hypothesis is supported by the fact in 
Ireland the incidence of NTD is also unusually high and this population has a high 
frequency of well documented "folate-sensitive" NTD risk factor, the c.C677T variant in 
the MTHFR (Kirke et al. 2004). Given that 90-95% of the Newfoundland population is of 
Irish or English ethnicity (Dr. Jane S. Green, personal communication), it is tempting to 
speculate that this allele is also frequent in NL; to date this allele frequency in our 
population has not been determined. 
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2B.3 The presence of(ounder effect (or certain Mendelian disorders and probably (or 
some complex traits: Founder effect is one form of genetic drift. If one of the original 
founders of a new subpopulation happens to carry a rare allele, that allele will have a 
much higher frequency than it had in the larger parental population. Founder effect is 
well illustrated by the Old Order Amish, a religious isolate of European descent that 
originally settled in Pennsylvania. The Amish have a high incidence of certain rare 
autosomal recessive conditions, including a form of dwarfism called Ellis-van Creveld 
syndrome. Other striking examples of founder effect include: variegate porphyria (an 
autosomal dominant late onset disorder) in the Afrikaner population of South Africa; type 
I tyrosinemia in the Quebec genetic isolate from the Lac Saint Jean region; and 
choroideremia (an X-linked degenerative eye disease) in the Finnish population 
(Nussbaum et al. 2001\ By definition if the prevalence of a disease in a genetic isolate is 
increased because of a founder effect, one or a very limited number of mutations (usually 
occurring on a shared, conserved haplotype) account for the majority of disease causing 
mutations in that population, even in apparently unrelated individuals. 
Founder effect has been observed in Newfoundland for a number of Mendelian disorders 
including: hereditary non-polyposis colorectal cancer syndrome (HNPCC) (Frogatt et al. 
1999; Green et al. 2002; Stuckless et al. 2007); multiple endocrine neoplasia type 1 
(MEN1)-Burin variant (Olufemi et al. 1998); hereditary diffuse gastric cancer syndrome 
(Kaurah et al. 2007); the Twilligate variant of hemophilia A (Xie et al. 2002); 
arrhythmogenic right ventricular dysplasia (Memer et al. 2008). Further details are given 
below: 
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#1 HNPCC: In 1999, an intron 5 splice site mutation in the MSH2 gene (A~T at 
nt943+3) was reported in 10/20 Newfoundland families. In contrast this so called "family 
C" mutation was present in only 8% of UK HNPCC families. In eight of the 
Newfoundland families, the mutation occurred on a common haplotype consistent with 
founder effect (Froggat et al. 1999). This founder MSH2 mutation has subsequently been 
identified in a total of 12 NL families (Green et al. 2002; Stuckless et al. 2007) and in a 
population based CRC cohort of 750 probands, there were 26 Amsterdam 1 criteria 
families, nine of which segregated the family C mutation (Dr. Michael 0. Woods, 
personal communication). 
#2 MENJBurin: One hundred and thirty eight MEN1 patients have been recorded in the 
Provincial Medical Genetics Program database, and 125 (90.6%) have a specific 
nonsense mutation in exon 10 of the MENJ gene (R460X), which is also known as the 
MEN1-Burin variant mutation. These Burin variant patients come from six families 
whose ancestors can all be traced to a resettled community in Fortune Bay, adjacent to 
Burin peninsula and the mutation has occurred on a common haplotype. Their phenotype 
is characterized by a relatively high frequency of prolactinomas and a low incidence of 
gastrinomas (Bear et al. 1985; Olufemi et al. 1998; Hao et al. 2004; Dr. Jane S. Green, 
personal communication; PMGP database). 
#3 Hereditary diffuse gastric cancer syndrome: In 2007, Huntsman et al. published the 
results of mutation analysis of the E-cadherin (CHDJ) gene on 38 families who met the 
criteria for hereditary diffuse gastric cancer syndrome. The cohort included four NL 
families who had the same mutation (2398delC). The 2398delC families all originate 
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from resettled communities within a 1 00-mile radius off the south east coast of NL 
(Marishene Island) and from St. Pierre and Miquelon. The four families contained 29 
cases of gastric cancer and 16 cases of lobular breast cancer, and all mutation carriers 
shared a common haplotype consistent with a founder effect mutation (Kaurah et al. 
2007). 
#4 Mild hemophilia A (Twillingate variant): In 2002, Xie et al. reported a founder 
mutation in the Factor VIII gene (valine 2016 -7 alanine) which explains the high 
prevalence of mild hemophilia in the province. 
#5. Arrhythmogenic right ventricular dysplasia (ARVD5): Fifteen Newfoundland 
ARVD families (containing 257 affected people) had the same disease associated 
haplotype on chromosome 3p25. In 2008, all patients with this haplotype were shown to 
have the same mutation in the TMEM43 gene (p.S3581L) (Memer et al. 2008). 
Complex trait genetics is a much younger field than its Mendelian counterpart, so that 
fewer Newfoundland "founder" susceptibility alleles have been identified. However one 
example, CARD15, is discussed below. 
The capsase recruitment domain gene (CARD15) is a susceptibility gene for Crohn' s 
disease and psoriatic arthritis (Hugot et al. 2001 ; Rahman et al. 20031; Rahman et al. 
20032). Dr. Rahman's group demonstrated a founder effect for a particular CARD15 
allele in the Newfoundland population. The p.Arg702Trp variant accounts for 71% of the 
NL CARD15 Crohn' s mutations, compared with 35% of European CARD15 mutations 
and 40 of Quebec CARD 15 mutations (Rahman et al. 20031; Lesage et al. 2002; Vermeire 
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et al. 2002). The p.Arg702Trp variant also accounts for ~70% of the CARD15 mutations 
associated with psoriatic arthritis in NL (Rahman et al. 20032). 
2C How does the Newfoundland population compare with other founder 
populations with respect to age? The appeal of isolates for molecular genetics research 
is related to their genetic homogeneity (with reduced allelic diversity), which is usually 
accompanied by greater environmental homogeneity than that of admixed populations. 
However, there are important differences between founder populations. These factors 
influence the isolate's disease allele diversity, which in turn determines its usefulness for 
gene hunting projects. Distinguishing parameters include: the number of founders; the 
time before population expansion began; the age and current size of the population; the 
amount of in-migration; and the presence and timing of historical bottlenecks (e.g. 
famines, epidemics of infectious diseases, wars) (Laitinen 2002; Varilo and Peltonen 
2004). 
The "old" genetic isolates are ~200-400 generations old and are usually demographically 
stable. Examples include the Basques of southwest Europe and the Saami (Lapps) of 
Scandinavia. The Saami forager population numbers about 50,000 and has been spread 
across a large land area because of the Saami' s source of livelihood. These older isolates 
have often lost their distinct spectrum of monogenic disorders and so have been largely 
ignored by molecular geneticists. 
Molecular genetic studies searching for alleles that confer susceptibility to complex traits 
have primarily targeted "middle-aged" genetic isolates. These are populations that had a 
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restricted nwnber of founders and that are 100-200 generations old. Examples include 
Finland (early settlement portion is~ 2,000 years old) and Iceland(~ 1,000 years old). 
Newfoundland belongs to the group of "very young" founder populations, which are 1 0-
20 generations old. Other examples include: the late-settled parts of Finland (~330 years 
old); the Central Valley region of Costa Rica; the Lac Saint Jean region of Quebec (~250-
400 years old); the Amish ( ~ 250 years old); the Canadian and US Hutterites ( ~ 130 years 
old); and the inhabitants of the Pacific island of Tristan da Cuhna ( ~ 100 years old) 
(Rahmanet al. 2003 1; Varilo and Peltonen 2004; Laitinen 2002). 
Younger isolates are expected to have a distinct pattern of over-represented monogenic 
disorders. For example in Finland, founder effect has produced a high incidence of 36 
monogenic (mainly autosomal recessive) disorders (Peltonen et al. 2004). However this 
does not necessarily translate to a net increase in the total frequency of Mendelian 
disorders in isolates. Certain Mendelian conditions are expected to be under-represented 
because these mutant alleles were not introduced into the population by its founders. To 
date, there have been no studies of founder populations which have measured the overall 
burden of genetic disease. Rather families from these populations have been used to 
identify genes causing specific monogenic disorders or the population has been studied at 
a theoretical level to estimate its value for the identification of complex trait 
susceptibility alleles. 
Along a similar vein, younger founder populations are not necessarily predicted to have a 
higher net genetic burden from complex diseases. However if the prevalence of a 
particular multifactorial disease is higher than in the general population, this might be 
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explained by the fact that usually rare, but highly penetrant susceptibility alleles have 
become more common in the isolate because of genetic drift. In 2005, Oen et al. reported 
that a complex disease, rheumatoid arthritis (RA), is enriched in the North American 
Native (NAN) population from Manitoba and Northwest Ontario. This isolate is 
comprised of Cree and Ojibway Indians and has a 5-fold increased rate of RA compared 
with North American Caucasian and European populations. In addition to a higher 
prevalence ofRA, the NAN have an earlier age of disease onset, greater disease severity, 
and higher familial prevalence, all suggestive of increased frequencies of RA 
susceptibility alleles due to genetic drift and founder effect. 
In Newfoundland, we would therefore expect to fmd an increased incidence of certain 
Mendelian diseases, with other monogenic disorders that occur less frequently than in 
admixed populations. One might also expect to fmd over-representation of a select 
number of complex diseases (see section 2B.3 for documented examples). 
Fragile X syndrome, due to mutations in the X-linked FMRJIFRAXA gene, is an example 
of a monogenic disorder that is less common in Newfoundland than in more admixed 
populations. In most populations, FRAXA syndrome is the most frequent inherited cause 
of mental retardation, occurring in 1 in 1,250 males and 1 in 2,500 females. Because of 
its high prevalence, FMRJ genetic testing is routinely ordered as part of the evaluation of 
any child with cognitive delay of unknown etiology. There are at least several thousand 
developmentally delayed individuals who have been evaluated through the Provincial 
Medical Genetics Program in St. John's and who have had FMRJ genetic testing. Only 
one family with molecularly confirmed FRAXA syndrome has been identified, and that 
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family is not originally from Newfoundland (Dohey et al. 2008; PMGP database). 
Interestingly the same paucity of FRAXA patients has been reported in Nova Scotia 
(Beresford et al. 2000). 
2D Previous studies of the burden of genetic disease among hospitalized children: 
Dating back at least to the 1950's, investigators have been interested in documenting the 
frequency of genetic disease in human populations. Such information is essential for 
planning rational health care strategies. In one of the earliest publications from 1959, 
Stevenson reported that 26% of all institutional beds in Ireland were occupied by patients 
with genetic disease. 
The strongest population-based study was published by Baird et al. in 1988 using data 
from the British Columbia Health Surveillance registry. This is an on-going population-
based registry with multiple sources of ascertainment. The authors estimated the 
population burden of genetic disease in over 1 million consecutive live births, and 
concluded that before age 25 years at least 53/1,000 liveborns can be expected to have a 
disease with an important genetic component. This total included single-gene disorders 
(3.6/1,000), chromosomal disorders (1.8/1,000) and multifactorial disorders present by 
age 25 (46.4/1,000). 
Hospitalization is one of the most expensive forms of medical care for genetic disease. 
There have been five previous studies which estimated the amount and distribution of 
genetic disease among children admitted to tertiary level pediatric hospitals. These are 
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discussed below and have been swnmarized in table 2-1. The present study shares many 
of the design features of these earlier studies. 
The other major group of pediatric genetic content studies are retrospective reviews of 
the causes of death of children admitted to either a pediatric hospital or to a children's 
intensive care unit. The results of three of these studies are as follows: 34% of 523 deaths 
in a Utah tertiary level pediatric hospital were due to malformations or genetic disorders 
(Stevenson and Carey, 2004); 19% of268 deaths in a pediatric ICU in a teaching hospital 
in Arkansas were due to a heritable disorder (Cunniff et al. 1995); and 45% of deaths 
over an 11-year period in a neonatal ICU in Kentucky occurred in patients with a major 
congenital malformation (Stewart and Hersh 1995). 
The above studies share some limitations. They are based on restrospective review of 
death certificates and/or medical records. Hence the authors relied on the healthcare team 
that cared for the child (which did not necessarily include a geneticist) to recognize and 
document the presence of a genetic disorder. Because the boundary between genetic and 
non-genetic disease has become blurred, classification of whether a particular disease was 
genetic or not was not always unequivocal. If a genetic disease was present, 
determination of whether the disease contributed to the child's death was sometimes 
subjective. 
For example Stevenson and Carey (2004) reviewed neonatal and pediatric deaths over a 
4-year period (1994-1998) in a university teaching hospital that has a neonatal and 
pediatric ICU and that is a regional referral center for cardiac surgery. Hence compared 
to a community pediatric hospital, there was undoubtedly referral bias towards children 
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with more complex medical problems which includes those with genetic diseases. The 
classification of the deaths was based on chart summaries prepared by the chief resident 
for monthly morbidity and mortality rounds, and these summaries were reviewed by the 
authors. There was no separate category for multifactorial diseases that led to death, and 
these were included in the non-genetic category. 
Cunniff et al. (1995) compared review of the medical record with review of the death 
certificate alone. When the medical record was reviewed, 51 pediatric ICU deaths were 
classified as attributable to a heritable disorder. The death certificate listed the heritable 
disorder in only 21 of these 51 cases. 
2D.1 Five previous studies of the burden of genetic disease among children admitted 
to a single tertiary-level pediatric hospital: PubMed was searched using the terms 
"pediatric hospital and genetic" and "genetic burden and pediatric". Five single hospital-
based studies were identified. 
1) Day and Holmes 1973: These authors published a review of 800 hospital records from 
the Massachusetts General Hospital, including 200 pediatric inpatients. Primary and 
secondary diagnoses and family history information were extracted from the hospital 
chart. The authors used a classification system in which each diagnosis was assigned to 
one of seven categories based on its genetic content: 1) single-gene; 2) chromosomal; 3) 
polygenic; 4) probably genetic; 5) developmental; 6) unknown and 7) environmental 
(which included all malignancies except Wilms tumor). Polygenic disorders were defined 
as conditions "considered to be due to additive effects of several minor gene 
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abnormalities ... with a sibling recurrence risk of at least 5%" (e.g. some isolated major 
congenital abnormalities, asthma, diabetes, psoriasis). The "probably genetic" conditions 
were defmed as diseases which showed familial clustering and for which a genetic 
etiology had been postulated (e.g. seizure disorders, migraines and benign familial 
macrocephaly). Developmental disorders were anomalies that arose from abnormal 
development, but that were not included in the polygenic group (e.g. undescended testes). 
The unknown category included conditions for which it was not possible to assign either 
a genetic or environmental etiology (e.g. cerebral palsy, Wilms tumor and mental 
retardation). Finally, the environmental group included diagnoses for which the authors 
felt that influences from the environment were the major cause of disease (infections, 
accidents, most malignancies). 
These authors found that 17% of pediatric inpatients had a primary diagnosis that was of 
genetic origin (i.e. either a single-gene, chromosomal or a polygenic disease). The largest 
contribution in the genetic group was made by the polygenic disorders. More specifically 
13% of the 200 admitted children had a primary diagnosis of a polygenic disorder, and 
28% of these had a positive family history for the same disorder. 4% of the admitted 
children had a primary single-gene or chromosomal diagnosis. 
2) Scriver et al. 1973: In the same year, Dr. Charles Scriver's group published a review 
of the medical charts of 1,089 children admitted to the Montreal Children' s Hospital. The 
charts were randomly sampled over a 12-month period from 1969-70, during which time 
the total number of admissions was 12,801. The discharge diagnosis and length of stay 
were extracted by reading the medical record (note that only the fmal diagnosis was 
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extracted). The discharge diagnoses were again divided according to their genetic 
content, this time into four categories: 1) genetic: single-gene, chromosomal or 
multifactorial diseases- the latter excluded birth defects; 2) congenital malformations; 3) 
unknown - probably genetic, but could not be assigned to either of the first two 
categories; 4) non-genetic. 
Scriver's group found that 11% of the discharge diagnoses were "genetic", 18.5% were 
"congenital malformations", and 6.7% were in the "unknown" category. The authors 
concluded that at least 30% of admissions to their pediatric hospital were due to the 
effects of "abnormal gene-environmental interactions". During that time frame, less than 
300 patients were referred to the genetics service, compared with the 4,000 pediatric 
patients whom they extrapolate were admitted with "genetic disease". They comment on 
the tremendous under-referral to their genetic service and on the fact that their genetic 
clinic would be unable to cope with such a referral volume. The paper includes a list of 
the 17 most common "genetic" discharge diagnoses (the two most common were atopic 
hypersensitivity and hemophilia A), and the 14 most common congenital malformations 
(the two most common were hernia and congenital hip dislocation). Among patients 
hospitalized for more than 1 0-days, the congenital anomaly group was over-represented. 
Moreover, patients with "genetic" illnesses accounted for 70% of the children with 
multiple admissions. 
3) Hall et al. 1978: In one of the largest studies to date, Dr. Judith Hall and colleagues 
reviewed 4,115 admissions to a 200-bed general pediatric hospital in Seattle. The study 
population was randomly selected from a total of 8,244 children admitted to this hospital 
29 
in 1973. The primary source of information was the discharge sheet which listed the 
primary admission diagnosis, however in over half of the cases the medical chart was 
reviewed to establish the cause of the admission. A diagnoses list was assembled for each 
patient and each diagnosis was put into one of the following five categories: 1) clearly 
genetic disorders - single-gene or chromosomal disorders; 2) multifactorial/polygenic 
conditions - this category included conditions for which, at the time, multifactorial 
recurrence risks were given after specific environmental and single-gene entities had 
been excluded, for example congenital heart disease, seizures, deafness, mental 
retardation, cleft palate, diabetes, allergies - note that mutlifactorial birth defects and 
multifactorial diseases that are not congenital were analyzed together 3) developmental 
anomalies - malformations for which the recurrence risk had not yet been established, 
e.g. esotropia, cryptorchidism, renal abnormalities, multiple congenital anomaly 
syndromes; 4) familial disorders - conditions for which a familial predisposition 
appeared to exist, but recurrence risk was thought be less than for categories 1 and 2, e.g. 
prematurity, cancer; 5) non-genetic disorders e.g. infections, trauma. 
Next, Hall's group assigned an overall category to each admission, which was defmed as 
the lowest category number from the diagnoses list (i.e. the diagnosis with the highest 
genetic contribution from the list). 
Of the 4,115 admissions, 4.5% had clearly genetic disorders, 22.1% had 
multifactorial/polygenic conditions, 13.6% had developmental abnormalities and 13.2% 
had familial conditions. 46.6% had non-genetic disorders. Patients with clearly genetic 
disorders (category 1) had an average of 5.3 admissions, compared to 1.6 previous 
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hospitalizations for patients with non-genetic conditions. The average length of 
hospitalization was 3.4 days for the genetic patients and 2.5 days for the non-genetic 
patients. Only 14 of the category 1 patients received genetic counseling. 
4) Carnevale et al. 1985: These authors reviewed 2,945 admissions to a 350-bed general 
pediatric hospital in Mexico. This was the first survey carried out in a developing country 
and included neonatal and pediatric admissions. Diagnoses were extracted from the 
discharge sheet and by reviewing the medical chart. For each patient, the diagnosis 
selected for category assignment was the one with the highest genetic designation. The 
authors used 5 categories: 1) single-gene disorders; 2) chromosomal disorders; 3) 
diseases of probable but complex genetic cause, including birth defects, multiple 
malformation syndromes, diabetes, asthma; 4) diseases of unknown cause in which role 
of genetic factors was not known e.g. cancer, prematurity; 5) non-genetic e.g. infections, 
trauma, malnutrition. Strongly genetic diseases (categories 1 and 2) accounted for 4.3% 
of all the admissions. Category 3 (probable but complex genetic cause) represented 
33.5%. Therefore, patients with genetic or partly genetic disorders accounted for 37.8% 
of the patients studied. These genetic patients had longer and more frequent admissions. 
Yoon et al. 1997: This is a population-based (rather than single hospital-based) study of 
pediatric separations. This group reviewed hospital discharge data from over 350,000 
patients from California and South Carolina, which captured over 95% of the admissions 
under age 20 years in these two states during 1991. Each case was classified using ICD-9 
codes extracted from Medicare claim forms and from the hospital discharge summary. 
Each admission was categorized into one of 17 broader lCD categories (e.g. "hereditary 
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metabolic or endocrine disorders", "CNS or eye defects"). Nearly 12% of the pediatric 
hospitalizations in the two states combined were due to birth defects or "genetic disease"; 
the latter was defined as a Mendelian or chromosomal disorder. This group of children 
stayed on average three days longer in hospital, and had 4.5 times greater in-hospital 
mortality than children hospitalized for other reasons. This 12% figure is considerably 
lower than the 30-40% reported by the previously described single hospital-based studies. 
This almost certainly reflects the fact that sicker more complex children tend to be 
referred to pediatric hospitals like the ones used in the above papers. Yoon's study is 
population-based and includes pediatric admissions to non-specialty hospitals where the 
case-complexity would have been lower. Moreover, these authors chose a narrow 
definition of genetic disease (Mendelian, chromosomal and birth defects) and excluded 
the complex diseases (e.g. diabetes, asthma, epilepsy) included in the studies by Day and 
Holmes, Scriver, Carnevale and Hall. 
5) McCandless et al. 2004: These authors reviewed 5,747 consecutive admissions 
representing 4,224 unique patients who were admitted in 1996 to a 244-bed pediatric 
hospital in Cleveland, Ohio. Each patient's record was reviewed until a genetic diagnosis 
was identified or eliminated. The initial review was performed using only electronic 
discharge diagnoses. If the admission could not be assigned to the category lA (single-
gene or chromosomal), the entire written medical chart was manually reviewed; over 
5,000 charts were reviewed in this way. The categories used for classifying each 
separation were modified from those used by Hall et al. 1978 and were: 
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Category I-Underlying conditions with a strong genetic basis 
lA - Single-gene or chromosomal 
m - MultifactoriaVpolygenic conditions (e.g. congenital heart disease, cleft 
lip/palate, autism) - includes both birth defects and complex traits with a sibling 
recurrence risk. 
IC- Heterogeneous causes, often genetic (MR., seizures) -i.e. mainly complex 
traits for which sibling recurrence risk has been identified. 
II - Birth defects without known genetic basis 
IIA- Malformations of unknown etiology (bladder extrophy) 
liB -Teratogenic disorders (F ASD) 
III: Acquired disorders with genetic predisposition (asthma, diabetes, cancer) - note 
that the other four studies all classified cancer in one of the non-genetic categories, so 
that this study's frequency in this category is comparatively high. See table 2-1. 
IV: Acquired disorders without genetic determinant (e.g. hypoxic ischemic 
encephalopathy) 
V: No pre-existing chronic medical condition (e.g. infection in previously healthy 
child, trauma) 
There were 1,949 admissions in category I, representing 34% of the total admissions. 
Within this group 10.8% had single-gene or chromosomal disorders and 14.5% had 
Category IB multifactoriaVpolygenic conditions. 37% had an acquired disorder with a 
genetic predisposition (category III). The mean length of stay was 40% longer for 
patients with a clearly genetic underlying diagnosis than for non-genetic admissions. 
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2D.2 Conclusions from previous pediatric inpatient studies: In summary, there have 
been five previous studies that have attempted to quantify the burden of genetic disease 
among hospitalized children. In each case, the sample was drawn from a single tertiary-
level pediatric hospital; however making direct comparisons between these studies is 
difficult. Firstly, the publications span almost four decades, over which time we have 
developed a better understanding of the genetic basis of many disorders. Secondly, no 
two studies have used exactly the same classification scheme for ranking the genetic 
content of the admissions. Moreover, information about the specific diagnoses within 
each genetic content category varies between studies, as does the degree of record review 
that was performed before assigning the hospitalization to a particular genetic content 
category. 
With the above caveats, table 2-1 below summarizes the genetic and non-genetic disorder 
frequencies reported in the five studies that preceded this study (Y oon et al. 1997 was 
excluded because this was not a single hospital-based study). If "strongly genetic" 
conditions are defmed as Mendelian and chromosomal disorders, these studies have 
identified frequencies of wholly genetic disorders among hospitalized children ranging 
from 4-10.8%. "Moderately genetic" diseases (birth defects and complex traits for which 
sibling recurrence risks are given) occurred with frequencies of 19.5-20.9%. Due to 
differences in the classification schemes used in the Scriver, Carnevale and McCandless 
studies, the proportion of moderately genetic separations could not be estimated (see 







Table 2-1: Comparison of proportion of genetic admissions between single hospital-
based studies (proportions are based the total number of hospitalizations in each 
dataset). 
Hospital Sample Single Chrom- High Low Complex Complex Non-genetic 
size gene osomal heritability heritability disease with disease 
birth birth sibRR with low 
defects defects RR 
(%) (%) (%) (%) (%) (%) (%) 





Scriver et al. Montreal 1,089 6.9 0.4 < 18.5° < 18.5° 3.85c < 70.4° < 70.4° 
1973 Children's (assumed to (assumed to 
include include Hospital 
malignancies) malignancies) 
Hallet al. Children's 4,115 4.18 0.63 10.2 9.3 10.7 18.2 
1978* Orthopedic (includes 




Carnevale et National 2,945 5.le 0.85 < 22.41 < 22.41 9.3 16.68 
al. 1985 Institute 
Peds., includes 
Mexico neonates 
McCandless Rainbow 5,747 9.5 1.29 < 24' < 9.44J < 59.6K < 45.1 





* see appendix C for details of how this study's dataset was reanalyzed using the genetic content 
categories from the present study. 
a 43 cases including 36 "urinary tract abnormalities", some of which we probably would have 
classified in our study as IIA (e.g. renal agenesis) or IllA (e.g. vesicoureteric reflux), but the 
break down of individual diagnoses was not given. 
b Scriver et al. did not distinguish between high heritability congenital abnormalities (e.g. 
congenital heart disease) and low heritability birth defects (e.g. tracheoeosophageal fistula). 
c In this group of 42 cases, there were 24 cases of "atopic hypersensitivity". The remaining 18 
diagnoses were not specified. 
d Scriver et al. did not distinguish between low heritability complex traits and non-genetic 
diseases 
elncludes 101 children with an identified single-gene disorder + 50 children with multiple 





f Congenital defects were listed as broad categories (e.g. congenital heart malformations, 
gastrointestinal anomalies), so that this group could not be broken down into high and low 
heritability birth defects. 
8 Includes 250 children with cancers/tumors + 37 with "cerebral palsy and other neural system 
disorders"+ 37 with "renal disorders"+ 156 with "miscellaneous" diagnoses. 
h This group consists of 1,341 children where the diagnoses were given as broad categories, e.g. 
"infectious diseases", "gastrointestinal", "nervous system". We likely would have categorized 
some of the specific diagnoses within each broad group as IIIb and others as IV. 
; Higher heritability birth defects appeared in three McCandless groups (IB, IC, IIA). The total 
number of separations in these three groups comprises 24% of their dataset, but these three 
groups also include non-congenital diagnoses and low heritability congenital anomalies. 
jLow heritability birth defects appeared in McCandless categories IC and IIA which together 
accounted for 9.44% of the dataset, but these two group also included other diagnosis (that we 
categorized as IIA, IliA, IIIB, ID, and IE). 
k Higher heritability non-congenital multifactorial diseases appeared in three McCandless groups: 
IB (14.5% of total separations); IC (8.6% of total separations) and ill (36.5 % of total 
separations). However each of these three groups contained other diagnoses not falling within our 
IliA group. 
1 Lower heritability non-congenital multifactorial diseases appeared in McCandless categories: IC 
(8.6% of their total separations) and ill (36.5% of their total separations). Both McCandless' 
groups contained other diagnoses not falling within our IIIB group. 
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In conclusion, over the past three decades, our understanding of the genetics of common 
and rare diseases has increased. Treatment options for genetic disease have expanded 
and some formerly fatal conditions are now compatible with long-term survival. 
Moreover the province of Newfoundland and Labrador has a unique founder population, 
and one could hypothesize that it contains more individuals affected with either strongly 
or moderately genetic diseases. 
Because knowledge of the amount of genetic disease that exists among hospitalized 
children is essential for designing health care strategies for the delivery of genetic 
service, we conducted a study of the burden of genetic disease among hospitalized 
children using the only tertiary-care pediatric hospital in this province. 
Our study design was similar to that of Hallet al. 1973 and McCandless et al. 2004. For 
each hospitalization, the minimum review included the ICD-9 discharge diagnosis(es) 
and the discharge summary dictation. We modified the classification scheme by using 
lambda s (A.s) and heritability estimates to divide the birth defects and non-congenital 
multifactorial diseases into more strongly and less strongly genetic categories. 
We used this classification method (which included 11 categories) to describe the genetic 
content of 4,144 consecutive NL pediatric hospitalizations (3,281 unique separations). 
We examined hospital utilization data by classifying each separation into one of three 
broader genetic content groups (strongly, moderately or weakly genetic). We used 
multivariate regression to examine the impact of the genetic content of an admission on 
length of stay (LOS). Finally, we described referral patterns among these hospitalized 
children, identifying groups of children who are under referred for genetic services. 
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As a prelude to the main part of this project, we conducted a validation study comparing 
our proposed method of determining the genetic content of a hospitalization to a gold 
standard (face-to-face interview and record review by a medical geneticist). Medical 
geneticists are physician specialists who are trained in the recognition and investigation 
of patients with strongly genetic diseases. We found that our study method had high 
enough sensitivity and specificity to allow us to apply it to the entire study sample. 
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CHAPTER3: 
METHODS & ANALYSIS 
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3A. METHODS - VALIDATION STUDY: Administrative databases are suboptimal 
for data extraction. Therefore, we embarked on a validation study to examine the 
accuracy of the retrieval of genetic diagnoses from hospital discharge summaries. 
In the main study, review of the index discharge summary by a research nurse was used 
to identify diseases that have a genetic component. This methodology is limited by the 
fact that it relies on the admitting pediatrician and/or house staff to recognize the 
presence of a genetic disorder in the admitted child and to mention this in the discharge 
summary, regardless of whether this influenced the child's hospitalization (for example 
polydactyly in a child admitted with gastroenteritis). We propose that a clinical interview 
of the parent and child by a medical geneticist, coupled with review of the inpatient 
record by this geneticist forms the best "gold standard" against which to judge the 
accuracy of other means of identifying such diseases. While this may be the case, it is not 
feasible to use this method for over 4,000 cases. 
We performed a validation study in which a random sample of201 pediatric cases (from 
January- October 2000) was reviewed by a gold standard method and by the research 
nurse method proposed for the main study. 
The participants were enrolled on one day per week over a 10-month period (an average 
of six children per week). The weekday selected depended on the availability of the 
geneticist (BF). On the selected day, the research nurse obtained the admission list from 
the previous night and a random numbers list was used to select the cases. 
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For each consenting case, the parent completed a face-to-face interview with the medical 
geneticist prior to discharge from hospital. The geneticist examined the child, reviewed 
the inpatient record and assigned the patient to one of 11 final genetic categories 
(described in section 3B.3). These cases were independently categorized by the project's 
research nurse through review of the ICD9 discharge codes, the index discharge summary 
and up to two previous discharge summaries (i.e. following the protocol outlined in 
section 3B.3). The accuracy of the latter method for "fmal category" and overall group 
assignment (group 1, 2 or 3, as defmed in section 3C) was calculated. 
3B.METHODS-MUUNSTUDY 
3B.l Study Population and Study Subjects: Pediatric separations from the Janeway 
Children's Health and Rehabilitation Centre4 were reviewed. Located in St. John' s, the 
provincial capital city of Newfoundland and Labrador, this 80-bed facility is the only 
tertiary-level pediatric hospital in the province. Sixty percent of all pediatric separations 
in the province occur from this hospital. Moreover, clinical genetic referrals are handled 
by a single provincial medical genetics program (PMGP), which is based at the Janeway 
Hospital with two outreach clinics. The program was established in 1986 and data on 
every referred patient has been entered into a database. Through cross-referencing the 
patients in the study population with the medical genetics database, those who received 
genetic services were easily identified. The database also captures children who have 
been referred to the PMGP who are waiting for an appointment or who failed to keep the 
appointment that was offered. 
4 Also referred to as the "Janeway Hospital". 
41 
The study population includes all pediatric patients admitted to the Janeway Children's 
Health and Rehabilitation Centre over a 14-month period between July 2000 to 
September 2001 (4,144 separations). A pediatric admission was defined as one involving 
a person between the ages of 1 month and 17 years. Neonates were excluded for several 
reasons. Firstly, those born in hospital and admitted to the nursery for routine newborn 
care are a fundamentally different population (that is essentially healthy), compared with 
children hospitalized because of a medical problem. Neonates admitted to the neonatal 
ICU represent a group that is potentially enriched for birth defects and other genetic 
diseases and is a patient population that warrants its own study. 
3B.2 Sample size calculation: The study's sample size was calculated to ensure that the 
smallest category from previous studies (the chromosomal group) would be adequately 
represented. The percent of children with a chromosomal disorder from four of the earlier 
studies was 0.4% (Scriver et al), 0.6% (Hall et al. 1978); 0.9% (Carnevale et al. 1985) 
and 1.29% (McCandless et al. 2004). For the sample size calculation, 1t was set at 1.3% 
and the width of the 95% confidence interval was arbitrarily set at 0.4%. 
The sample size formula for estimation of a population proportion is: 
Sample size= 1t (1- 1t) (Zan I Cii 
Where 1t = the smallest proportion that should be detected with a high level of 
confidence. 1t = 1.3% ; CI selected at 0.4% and a = 0.05 
Sample size= 0.013 x (1 - 0.013) x (1.96/0.004i = 3,081 separations 
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The chromosomal frequency in the above four studies was determined from the total 
number of separations which included some children who had been hospitalized more 
than once in the study period. Nevertheless, we interpreted the sample size calculation 
conservatively and set the sample size at a minimum of~ 3,100 unique admissions. 
We reviewed 4,144 consecutive separations. 863 of these were repeat admissions of the 
same child, leaving 3,281 unique hospitalizations. 
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3B.3 Data extraction and outcomes: The Newfoundland and Labrador Centre for 
Health Information Services (NLCHI) reviewed its data tapes from the Janeway 
Children's Health and Rehabilitation Centre over the study period. Lists of unique 
separations were provided, including the following discharge data: the ICD9 discharge 
diagnosis codes, length of stay, number of surgical procedures, total cumulative inpatient 
days (from birth up to and including the index admission), and the "case mix group" 
(CMG) code. The CMG code is assigned by the Canadian Institute for Health 
Information (CIHI), and is described in more detail in section 3C.4. 
For each separation, the most recent discharge summary was reviewed. If the patient was 
admitted previously, the research nurse also reviewed the two most recent previous 
discharge summaries. The attending physician or house staff dictates the discharge 
summary when the patient is released from hospital. On average, these are 1-3 pages in 
length and each summarizes the patient's course in hospital including the results oftests 
and the final diagnoses. Almost all the discharge summaries over the study period were 
available electronically, so that retrieval of the hospital chart was rarely necessary. Based 
on the ICD9 discharge codes, review of the index discharge summary and review of up to 
two previous summaries, a list of diagnoses was determined for each index separation. 
For each hospitalization, each diagnosis from the list was assigned to one of the 
following 11 categories (see Appendix A for list of the diseases in each category): 
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lA: Chromosome disorder 1 
IB: Single-gene disorder 2 
IC: Teratogen3 - included within category I because such patients often have 
birth defects and/or dysmorphic features. Differential includes chromosomal and 
Mendelian syndromes so that genetic consultation is indicated. 
ID: Genetic syndrome identified, but precise mechanism of inheritance unknown2 
(e.g. Hallerman-Streiff syndrome) 
IE: Unidentified genetic syndrome likely exists and referral to a geneticist is 
indicated (e.g. multiple congenital anomalies; developmentally delayed child who 
has a birth defect) 
IIA: Multifactorial birth defect with known sibling recurrence risk4 (e.g. cleft 
lip). 
Im: Birth defect with low recurrence risk4 (e.g. congenital diaphragmatic hernia). 
IliA - Disease with a known genetic predisposition, including with heritability 
(h2) 2: 50% [e.g. asthma, autism spectrum disorder] or with Lambdas (A.s) 2: 10 
[e.g. type I diabetes] 5 
IIIB - Disease with multiple known causes, sometimes genetic, including those 
with h2 < 50% or A.s < 10 [e.g. atopic dermatitis ]5 
IV - Acquired disease with no or low genetic contribution (infection, trauma). 
V- No disease. 
1 
as per Gardner and Sutherland, 1996 
2 as per McKusick's Online Mendelian Inheritance in Man (OMJMTMJ 
3 
as per Friedman and Hanson 2002 
4 
as per Harper 2003 
5 
as per King eta/. 2002 
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The final category for each separation was the lowest numerical assignment that appeared 
among the diagnoses list, and that was related to the patient's need to be hospitalized. 
Initially, a single research nurse classified the separations, however before a final 
category was assigned, one medical geneticist (thesis author BF) reviewed each diagnosis 
list. The geneticist used knowledge of the phenotype to make a subjective determination 
about whether or not the genetic diagnosis made an important contribution to the 
patient's need to be hospitalized. For example, if a patient with cystic fibrosis is admitted 
with pneumonia, a clearly causal relationship exists, and the separation was classified as 
ffi (single-gene disorder). However, if a boy is admitted with gastroenteritis and happens 
to have a limb reduction defect which did not contribute to his need to be hospitalized, 
the final category was assigned as IV (acquired disease). 
While most of the analysis was done using the "final category", in order to allow our 
data to be compared with some of the earlier studies, each separation was also assigned a 
"hierarchical final category" defmed as the lowest numerical assignment that appeared 
among the diagnoses list, regardless of whether it contributed to the patient's need to be 
hospitalized. 
3C. ANALYSIS: Most of the data analysis was performed using the "final category" of 
each hospitalization, as described above. Because of relatively small numbers in each of 
the fmal categories, these were stratified into three groups based on heritability. These 
groups were used for the hospital utilization analyses and are as follows: 
• Group 1: separations with a strongly genetic fmal category, i.e. IA, ffi, ID, IE. 
• Group 2: separations with a moderately genetic fmal category i.e. IIA, IliA. 
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• Group 3: separations with a minimally or non-genetic final category i.e. IC, liB, 
IIIB, IV, V. 
In order to allow our data to be compared to earlier studies of the burden of genetic 
disease among hospitalized children, it was reanalyzed in the following way. Each 
separation was assigned a "hierarchical final category" defined as the most strongly 
genetic diagnosis from the diagnoses list regardless of whether this diagnosis influenced 
the patient's need to be admitted or the course of the hospitalization. 
3C.l Analysis of the validation study data: Over an 8-month period, 201 pediatric 
inpatients from the Janeway Hospital were randomly selected, and informed consent was 
obtained from the child's parent or guardian. The admission was assigned a "fmal 
category" by the gold standard method (interview and record review by a clinical 
geneticist) and by the research nurse-method used in the broader study. The accuracy of 
the research-nurse method for assigning the final category (one of 11 choices) was 
calculated. The accuracy of this method for assigning separations to one of three genetic 
content groups (strongly, moderately or weakly genetic) was also calculated. 
3C.2 Determination of the genetic content of 4,144 hospitalizations: The study's 
Accesstm database was converted into an SPSS file. Analyses were performed on the 
SPSS file to determine the following: 
• The total number of diagnoses for 4,144 consecutive hospitalizations, the average 
number of diagnoses per hospitalization and the proportion of the total diagnoses that 
fell into the strongly, moderately and minimally genetic groups (groups 1-3 above). 
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• For 4,144 consecutive separations, the frequencies in each of the 11 "fmal category" 
groups (lA, IB, IC etc), and the frequencies when these fmal categories were stratified 
into three groups based on the burden of genetic disease (groups 1-3). 
• The analysis described in the previous bullet was repeated for 3,281 unique 
separations. 
• To allow our data to be compared to earlier studies, each of the 4,144 separations was 
reassigned a "hierarchical final category" and the frequencies in the 11 genetic 
content groups (lA, IB, IC etc) were recalculated. The data analysis in the earlier 
pediatric hospitalization studies was mainly done using the total number of 
separations rather than just the unique ones. 
• In order to look for trends supportive of the hypothesis that certain genetic problems 
are over-represented in the NL population, the 3,281 unique separations were 
analyzed in the two ways. Firstly, the frequencies of the most common specific 
diagnoses within four of the 11 "hierarchical fmal categories" were calculated: IA 
(chromosomal); IB (Mendelian disorders): IIA (high heritability birth defects); and 
IliA (high heritability complex diseases). Secondly, for unique separations that were 
assigned to a IB "hierarchical fmal category", the frequencies of the specific 
diagnoses grouped by modes of inheritance were determined. 
3C.3 Analysis of hospital utilization data: As described in section 3B.3, the "fmal 
category" of each of the 4,144 consecutive hospitalizations was used to stratify them into 
three groups (strongly, moderately and minimally genetic). The total number of 
separations, rather than the unique number, was used because we were interested in 
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quantitating the net burden that children with genetic disorders place on the hospital 
system. 
For each group, we calculated the mean length of stay (LOS) in days, along with the 
standard deviation (SD) and the 95% confidence internal (CI). The means between the 
three groups were compared using an ANOV A test. 
We determined the sum of the person years in each of the three genetic content groups, 
and used this to calculate the cumulative surgeries per person years and the cumulative 
hospital days per person years for each of the groups. The rates between the three groups 
were compared using the chi-square test (6 x 6 cross table relationship). 
3C.4 Multivariate regression to test the hypothesis that the genetic content of an 
admission influences the length of stay: Analysis of Covariance (ANCOV A) was used 
to test the main and interaction effects of three factors (including the "final category" of 
the separation which reflects its genetic content) plus one covariate (age at 
hospitalization) on length of stay (LOS). This model was selected because it allows use 
of both categorical and continuous variables and can incorporate categorical variables 
with multiple items (e.g. the final category was one of 11 items). The analysis was 
performed on 3,281 unique separations to avoid bias from repeat sampling. 
The model's dependent variable was LOS which is a continuous variable. The 
independent variables in the model were one covariate (age at admission, also a 
continuous variable) and three factors which are categorical variables: sex; "fmal 
category" of the separation; and the 20 most common "Case Mix Groups" (CMG's). 
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The "Case Mix Group" code is further discussed below, but suffice it to say that the 
CMG factor reflects the main diagnosis that led to the patient's requirement for 
hospitalization. It consists of 20 variables (the 20 most frequently occurring CMG's in 
the dataset) which were compared to a reference variable (all other CMG's not falling 
into the group of the 20 most frequent). The 20 most common CMG's accounted for 
1,759 ofthe 3,281 unique hospitalizations (53.6%). 
Regarding the CMG codes, provincial hospital utilization data are collected and collated 
by the Newfoundland and Labrador Centre for Health Information Services (NLCHJ). 
These data are forwarded to the Canadian Institute for Health Information (CIHJ); each 
hospitalization's CMG is assigned at the national level by CIHI. The "Case Mix Group" 
is the acute inpatient grouping that forms the foundation of much of CIHI' s statistical 
analyses. The CMG is determined by the patient's "Most Responsible Diagnosis" 
(MRDx), coupled with any operative procedures that occurred during the hospitalization. 
In turn the MRDx is considered to be "the one diagnosis that describes the most 
significant condition of a patient that causes his/her stay in hospital". The MRDx is used 
to assign the patient to one of 25 "Major Clinical Categories" (MCC) which identify 
either a body system (e.g. respiratory system) or other specific types of clinical problems 
(e.g. mental disorders, burns). Within each MCC, based on the presence or absence of an 
operative procedure, the case is directed towards a surgical or medical hierarchy. The 
CMG's were originally numbered from 1-999, but subsequently many have been 
dropped, so that only 397 are currently in use. (CIHI website; personal communication 
with Ms. Kerry LeFresne, NLCHI, February 2006). 
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3C.5 Analysis of referral pattern data: This analysis was performed using 3,281 unique 
hospitalizations classified using the "hierarchical fmal category", as described in section 
3B.3. Each child was cross-referenced to the Provincial Medical Genetics Program's 
database to determine if genetic services had ever been received. The proportion of 
patients in each category that had been referred was calculated. A priori, we decided that 
an acceptable clinical genetics referral rate for categories lA, m, IC, ID, and IE was ::: 
80%. 
We selected 60% as an acceptable referral rate for the IIA group (heritable birth defects). 
While selection of the cut-off was somewhat arbitrary, we decided that the IIA referral 
rate should be lower than the 80% cut-off for groups lA, IB, ID, IE where a genetics 
consult is essentially always indicated. Children with many of the IIA birth defects that 
are relatively prevalent in the general population (including spina bifia, cleft lip and 
palate) should be referred for genetic services. However, there are other IIA diagnoses 
which, while associated with an appreciable recurrence risk, do not otherwise warrant a 
genetics consult. This recurrence risk should ideally be reviewed with the parents 
although not necessarily by a genetics health professional. Examples of such IIA 
diagnoses include: some noncomplex forms of congenital heart disease including aortic 





4A RESULTS OF VALIDATION STUDY: As compared with the gold standard 
(geneticist interview), the discharge swnmary based method of assigning a final category 
had an overall accuracy of 94% (95% CI 0.90-0.97). 189 of 201 separations were 
assigned to the same final category (one of 11 categories IA-IV, as described in 3B.2) by 
both methods. Twelve cases were assigned to different final categories. 
All 29 separations with a group 1 (strongly genetic) fmal category were correctly 
assigned to group 1 by the discharge summary method, which suggests that the larger 
study should identify almost all admitted children with a chromosomal or Mendelian 
disease that a clinical geneticist would recognize. Part of the reason that the detection rate 
for a group 1 diagnoses was so high is that category IE captures "syndromic" children 
with multiple congenital anomalies and/or developmental delay, even though a specific 
syndrome has not been diagnosed. Moreover the IE label can be applied based on the 
contents of the discharge summary even if the existence of a syndrome was not queried 
by the person that dictated the discharge summary. For 1/29 group 1 separations, the 
research nurse incorrectly assigned a IE diagnosis (multiple birth defects suggestive of a 
syndrome) rather than a IB diagnosis (Mendelian syndrome) assigned by the clinical 
geneticist. 
Of the 12 hospitalizations which were assigned to different fmal categories by the two 
methods, in only 6 cases did this lead to a different WYQ assignment (group 1, 2 or 3, 
see section 3C) as shown in the table below. For example, 61 cases were assigned to 
group 2 by the gold standard, and of these three were mislabeled as group 3 by the 
discharge swnmary method. Similarly of 111 hospitalizations assigned to group 3 by the 
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gold standard, three cases were incorrectly assigned to group 2 by the discharge summary 
method. Therefore the overall accuracy of the discharge summary method compared to 
the geneticist interview method for group assignment was (201-6)/201 = 97% (95% CI 
0.94-0.99). 
Table 4-1: Comparison of the categorization of 201 pediatric hospitalizations by 








Gold Standard -Interview 
Gp1 Gp2 Gp3 
29 0 0 
0 58 3 
0 3 108 






For the remaining six discrepant cases, the difference in "fmal category" did not result 
in a difference in the overall group classification, as shown below: 
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Table 4-2: Number of separations that were categorized differently by the discharge 
summary method compared with the gold standard, but for which the miscategorization 
did not change the genetic content group. 
Number of Discrepancy 
discrepant (gold standard vs. discharge separations 
within group summary classification) 
Group 1 1 m vs. IE 
Group2 0 -
Group3 5 liB vs. IIIB 
rrm vs. IV 
IV vs. IIIB 
IC vs. IV 
IIIB vs. IV 
TOTAL 6 
From the validation study, we concluded that the discharge summary based method of 
determining the genetic content of an admission (as described in section 3B.3) was 
surprisingly accurate and therefore applied this method to the main dataset. 
4B DETERMINATION OF GENETIC CONTENT OF 4,144 SEPARATIONS: 
4B.1 Description of the distribution of the genetic content of 4,144 consecutive 
separations and 3,281 unique separations: The study population was defined as all 
pediatric patients admitted to the Janeway Hospital over a 14-month period (07 /00-
09/01 ). 4,144 consecutive pediatric hospitalizations were reviewed and categorized using 
the methods described in section 3B.3. 
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From the 4,144 separations, we retrieved 9,812 individual diagnoses, giving an average 
of 2.4 diagnoses per hospitalization. The frequency in each of the 11 categories of 
diagnosis is listed in table 4-3. When the individual diagnoses were categorized 
according to the burden of genetic disease, 3.8% were strongly genetic and 22.5% 
were moderately genetic (table 4-4). 
Table 4-3: Category breakdown of9,813 diagnoses for 4,144 consecutive patients. 
Category of Number of Diagnoses Percent 
Dia211osis 
IA 45 0.46 
IB 183 1.86 
IC 28 0.29 
ID 12 0.12 
IE 128 1.30 
IIA 531 5.41 
IIB 480 4.89 
IliA 1,681 17.13 
IIIB 2,666 27.16 
IV 4,004 40.80 
v 54 0.55 
TOTAL 9,813 100 
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Table 4-4: 9,812 diagnoses for 4,144 consecutive patients stratified into three groups 
based on the burden of genetic disease. 
Genetic Category of Number of Percent 
Burden Diagnosis Diagnoses 
Group 1: lA, IB, ID, IE 368 3.8 
Strongly 
Genetic 
Group 2: IIA, IliA 2,212 22.5 
Moderately 
Genetic 
Group 3: IC, liB, IIIB, 7,232 73.7 
Minimally IV,V 
Genetic 
TOTAL 9,812 100 
Then each of the 4,144 consecutive separations was assigned a "final category" defined 
as: the lowest numerical assignment (i.e. the most strongly genetic diagnosis) that 
appeared among the patient's diagnoses list and that contributed to the patient's need to 
be hospitalized or to the length or course of his/her stay (table 4-5). 
33.2% of the 4,144 hospitalizations were attributed to either a strongly or 
moderately genetic disease (8.3% and 24.9% respectively). See table 4-6. 
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Table 4-5: Distribution of the "Final Category" for 4, 144 consecutive hospitalizations. 
Final category of Number of Percent 
hospitalization Hospitalizations 
lA 39 0.94 
IB 160 3.87 
IC 22 0.53 
ID 10 0.24 
IE 133 3.21 
IIA 220 5.32 
liB 150 3.60 
IliA 813 19.63 
IIIB 1184 28.62 
IV 1370 33.10 
v 43 1.04 
TOTAL 4,144 100 
Table 4-6: "Final Category " for 4,144 separations, stratified into three groups based on 
the burden of genetic disease. 
Genetic Burden Final category of Number of Percent 
hospitalization hospitalizations 
Group 1: IA, IB, ID or IE 342 8.3 
Strongly Genetic 
Group 2: IIA, IliA 1,033 24.9 
Moderately Genetic 
Group 3: IC, liB, IIIB, IV 2,769 66.8 
Minimally Genetic or V 
TOTAL 4,144 100 
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Figure 4-1: Proportion of 4,144 consecutive separations classified by 'Final Category" 
into three broader genetic content groups. 
group 1 (strongly genetic) 
group 2 (moderately genetic) 
group 3 (weakly genetic) 
In order compare our data to earlier studies of the burden of genetic disease among 
hospitalized children (see Discussion, section 5B.1), it was reanalyzed and each 
separation was assigned a "Hierarchical Final Category" defmed as the most strongly 
genetic diagnosis from the separation's diagnoses list regardless of whether this 
diagnosis influenced the patient's hospitalization. See tables 4-7, 4-8, 4-9 and 4-10. 
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Table 4-7: Distribution of "Hierarchical Final Category " for 4,144 consecutive 
admissions. 
"Most Genetic Final Total number of Percent 
Category" of the Hospitalizations 
hospitalization 
IA 43 1.0 
IB 173 4.2 
IC 8 0.2 
ID 12 0.3 
IE 122 2.9 
liA 296 7.1 
liB 169 4.1 
IliA 971 23.4 
liiB 1,148 27.7 
IV 1,1 60 28.0 
v 42 1.0 
TOTAL 4,144 -100.0 
Table 4-8: Distribution of "Hierarchical Final Category" for 3, 281 unique 
admissions. 
"Most Genetic Final Number of unique Percent 
Category" of the hospitalizations 
hospitalization 
IA 30 0.91 
IB 120 3.66 
IC 7 0.21 
ID 10 0.30 
IE 71 2.16 
liA 217 6.61 
liB 137 4.18 
IliA 778 23.71 
liiB 809 24.65 
IV 1063 32.40 
v 39 1.19 
TOTAL 3,281 -100.0 
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Table 4-9: "Hierarchical Final Category" for 4,144 consecutive separations, stratified 
into three groups based on the burden of genetic disease. 
Genetic Burden Hierarchical Number of Percent 
fmal category of hospitalizations 
hospitalization 
Group 1: IA, IB, ID or IE 350 8.4 
Strongly Genetic 
Group 2: IIA, IliA 1,267 30.6 
Moderately Genetic 
Group 3: IC, liB, IIIB, IV 2,527 61.0 
Minimally Genetic orV 
TOTAL 4,144 100 
Table 4-10: "Hierarchical Final Category" for 3,281 unique separations, stratified into 
three groups based on the burden of genetic disease. 
Genetic Burden Hierarchical Number of Percent 
fmal category of hospitalizations 
hospitalization 
Group 1: IA, IB, ID or IE 231 7.0 
Strongly Genetic 
Group 2: IIA, IliA 995 30.3 
Moderately Genetic 
Group 3: IC, liB, IIIB, IV 2055 62.6 
Minimally Genetic orV 
TOTAL 3,281 -100 
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4B.2 Description of the most frequent specific diagnoses associated with 4 of the 11 
hierarchical final categories: The individual diagnoses within four of the 11 
"hierarchical fmal categories" (lA, IB, IIA and IliA) were reviewed, looking for trends 
that support the hypothesis that NL is enriched for particular genetic conditions. Table 4-
11 lists the most common specific diagnoses within each of the above four categories, as 
well as the number of unique cases associated with each diagnosis. The diagnosis 
frequencies were calculated as the number of unique individuals with that particular 
diagnosis divided by the number of unique patients within that category. 
For example, during the 14-month study period, there were 43 hospitalizations that were 
assigned a hierarchical fmal category of lA (chromosomal disorder). However, 13 of 
these were repeat admissions. 
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Table 4-11: Description of the most frequent specific diagnoses associated with the 
"hierarchical final categories" IA, IB, IIA, and IliA, for 3,281 unique separations. 
Most Genetic #of #of unique Specific diagnosis # of % 
Final separations separations unique within 
Catego_rr cases cat. 
lA 43 30 Down syndrome 14 46.7% 
(chromo-
somal) Microdeletion syndromes 10 33.3% 
Microdeletion 22q 11 4 13.3% 
Angelman I Prader Willi 4 13.3% 
syndrome 
Turner syndrome 2 6.7% 
m 173 120 Cystic fibrosis 17 13.4% 
(single-gene) (AR) 
Familial adenomatous 4 3.1% 
polyposis (AD) 
Factor V Leiden (AD) 4 3.1% 
1-Cell disease (AR) 3 2.4% 
Neurofibromatosis -1 3 2.4% 
(AD) 
Noonan syndrome (AD) 3 2.4% 
Congenital adrenal 3 2.4% 
hyperplasia (AR) 
Metachromatic 2 2.4% 
leukodystrophy (AR) 
IIA 296 217 Congenital heart disease 52 24.0% 
(heritable birth Neural tube defect 39 18.0% 
defects) 
Pyloric stenosis 27 12.4% 
Cleft lip &/or palate 25 11.5% 
Cryptorchidism/ 16 7.4% 
hypospadias 
Microcephaly 13 6.0% 
Hearing loss (congenital 10 4.6% 
with no environmental cause) 
Club foot 9 4.1% 
Brain malformation 6 2.8% 
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Most Genetic #of #of unique Specific diagnosis #of 0/o 
Final separations separations unique within 
Cate2ory cases cat. 
Imperforate anus 6 2.8% 
Hirschsprung disease 4 1.8% 
IDA 971 778 Asthma 302 38.8% 
(heritable 
complex Seizures 80 10.3% 
diseases) (recurrent & non-febrile) 
Insulin dependent 76 9.8% 
diabetes 
Developmental delay 68 8.7% 
Depression 42 5.4% 
Attention deficit 41 5.3% 
hyperactivity disorder 
Crohn' s disease + 36 4.6% 
Ulcerative Colitis 
V esicoureteric reflux 35 4.5% 
Febrile seizures 31 4.0% 
Autism 15 1.9% 
Scoliosis 12 1.5% 
Juvenile rheumatoid 9 1.2% 
arthritis 
For the specific diagnoses within the IB hierarchical final category, Table 4-12 gives a 
breakdown of the modes of inheritance of these diagnoses, i.e. autosomal dominant; 
autosomal recessive; X-linked recessive; X-linked dominant; or mitochondrial. For some 
diagnoses, classification was not possible because the disease is genetically 
heterogeneous, with more than one possible mode of inheritance. 
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Table 4-12: Distribution of the modes of inheritance for the specific single-gene 
diagnoses within the IB "hierarchical final category", representing 127 unique 
hospitalizations. 
Mode of inheritance of m Number of unique cases Percentage of total single 
specific diagnosis gene disorders 
Autosomal dominant 51 40.2% 
Autosomal recessive 50 39.4% 
X-linked recessive 5 3.9% 
X-linked dominant 1 0.79% 
Mitochondrial 2 1.6% 
Mixed modes of inheritance 18 14.2% 
TOTAL 127 100% 
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4C THE IMP ACT OF AN ADMISSION'S GENETIC CONTENT ON THE 
UTILIZATION OF HOSPITAL RESOURCES: The "fmal category" of each of the 
4,144 consecutive admissions was used to stratify them into three broader genetic content 
groups (strongly, moderately and weakly genetic). For each group, we calculated the 
mean length of stay (LOS) in days, the standard deviation (SD) and the 95% confidence 
interval (CI), as show in table 4-13. 
The ANOVA test showed that there was a statistically significant difference in the mean 
LOS between at least two of the groups. When a Bonferroni correction was applied, the 
difference between all three pairs of groups was statistically significant. 
Table 4-13: Impact of the "final category" on length of stay (LOS) for 4,144 consecutive 
separations. 
Strongly genetic Moderately 
=Group 1 genetic = group 2 
(Final categories (Final categories 
IA,IB,ID,IE) IIA, IliA) 
N(#of 342 1,033 
separations) 
Mean LOS 8.01 (26.96) 6.37 (9.69) 
in days (SD) 
95%CI 5.14 - 10.08 5.78-6.97 
ANOV A: Group 1 versus group 2 p = 0.04 
Group 2 versus group 3 p < 0.001 
Group 1 versus group 3 p < 0.001 
Minimally genetic = TOTAL 
Group3 
(Final categories ID, 
liB, Ilffi, IV, V) 
2,769 4,144 
3.99 (6.57) 4.92 (1 0.68) 
3.75-4.24 4.59-5.24 
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We determined the sum of the person years for each of the three groups as way of 
correcting cumulative surgeries and cumulative hospital days for the patient's age. We 
used the sum of the person years for each group to calculate the cumulative surgeries per 
person years and the cumulative hospital days per person years for each group. This is 
shown in table 4-14. The rates between the three groups were compared using the chi-
square test (6 x 6 cross table relationship). For both cumulative surgeries and for 
cumulative hospital days, there was a statistically significant difference across the three 
genetic content groups. 
Table 4-14: Impact of "final category" on cumulative surgeries and cumulative hospital 
days, for 4, 144 consecutive separations. 
Strongly Genetic Moderately Minimally Genetic 
=Group 1 Genetic = Group 2 =Group3 
(Final Categories (Final Categories (Final Categories ID, 
IA,IB,ID,IE) IIA, IliA) liB, IIIB, IV,V) 
N (#of 342 1,033 2,769 
separations) 
Sum of 2,337 7612.89 20,154.52 
person years 
Cumulative 706 I 2337 1,266 I 7,612.89 3,472 I 20,154.52 
surgeries I = 0.302 = 0.166 = 0.172 
person years 
Cumulative 
hospital 31,809 I 2,337 27,552 I 7612.89 71,615 I 20,154.52 
days/ person = 13.61 =3.62 = 3.55 
years 
Cumulative surgeries per person years: i = 160.546 
(p-value < 0.0001; correlation= .06705) 
Cumulative hospital days per person years: i = 4002.292 




In order to allow our LOS data to be compared to the McCandless et al. 2004 study, we 
determined the mean age at admission and the mean LOS for our consecutive admission 
dataset by "hierarchical final category" (table 4-15). Children with Mendelian diseases 
(IB) and teratogenic exposures (I C) had the longest mean hospitalizations (1 0.6 d and 
15.3 d respectively). 
Table 4-15: Mean age and length of stay for 4,144 consecutive admissions by 
"hierarchical final category". 
Hierarchical Number of Mean age at 95% CI for Mean LOS 
final separations admission age 
category (years) (years) (days) 
lA 44 6.58 4.93- 8.24 5.59 
IB 172 8.61 7.69- 9.52 10.57 





IC 8 1.70 -0.26- 3.67 15.38 -0.551-31.31 
ID 12 9.20 6.20- 12.21 5.58 2.01 - 9.15 
IE 122 5.64 4.75- 6.52 5.48 3.61 - 7.35 
IIA 296 5.28 4.69-5.87 6.24 5.12- 7.36 
liB 169 5.77 4.90-6.64 4.24 3.46- 5.02 
IliA 971 8.09 7.74 -8.44 6.40 5.78-7.02 
IIIB 1148 8.15 7.82 - 8.49 4.41 4.04- 4.78 
IV 1160 7.19 6.88-7.50 2.97 2.69-3.25 
v 42 0.47 -0.25- 1.19 3.93 2.54-5.32 
TOTAL 4,144 7.41 7.24-7.58 4.92 4.59-5.25 
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Figure 4-2: Test of the "homogeneity of regression slopes assumption " showing that 
there is a significant interaction between two of the model's variables: "age at 
admission" and "final genetic content category". 
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For example for children with a fmal category of lA (chromosomal) or IliA (heritable 
multifactorial disease), LOS increases with increasing age, presumably reflecting the 
natural history of these conditions. Children with a final category ofiB (Mendelian) or IC 
(teratogen) show the opposite pattern, with longer lengths of stay at younger ages. This 
makes intuitive sense because syndromic looking children generally have a chromosome 
analysis as a "first line" test (this may be ordered by the pediatrician prior to genetic 
consultation) so that such children rarely require early prolonged hospitalization in order 
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to reach a diagnosis. On the other hand, IB and IC children are frequently hospitalized 
early in life for a diagnostic work-up which involves consultation by several specialists, a 
dysmorphology assessment and genetic testing that cannot easily be ordered by a 
pediatrician. Therefore an interaction term (age x fmal category) was included in the 
model. 
When the model was run, the following factors had significant p values of< 0.001: final 
category alone; CMG code; and final category x age. Partial eta squared refers to the 
percent of the total variance of LOS that is explained by the variable which was 2.2% for 
final category alone; 3.6% for CMG code and 1.4% for age x final category. The p 
values for age alone (p=0.226) was not significant. In other words, when adjusted for the 
other variables (gender, final category, CMG code, and the interaction between final 
category and age), age alone was not a significant predictor of LOS. The p-value for 
gender alone (p=0.111) was also not significant. 
Overall, the model was a relatively weak predictor of LOS. The significant variables 
(fmal category, CMG code, and age x final category) only explained 8.6% of the variance 
in length of stay. 
The strength of the model improved when we removed the 21st CMG group and restricted 
the analysis to the 1,759 children captured by the 20 most common CMG codes. Then all 
variables apart from gender had significant p values: final category alone (p=0.005; 1.4% 
of variance in LOS); CMG code (p < 0.001; 25.4% of variance); age alone (p=0.49; 0.2% 
of variance); interaction term of age xfinal category (p < 0.001 ; 3.1% of variance). R2 = 
0.338 which means that the model explains ~34% of the variance in LOS, with clearly 
71 
the largest part of this attributable to the CMG code rather than to the genetic content of 
the admission. 
The strength of the model did not improve when the final category was simplified as "IA 
(chromosomal) or IB (Mendelian)" versus "all other final categories". The "IAIIB 
group" contained 42 cases and the "other fmal category" group contained 1,717. The only 
variable with a significant p value (p < 0.001) was the CMG code which accounted for 
30% of the variance of the length of stay. Neither the simplified final category or the 




4E CLINICAL GENETIC REFERRAL RATES AMONG HOSPITALIZED 
CHILDREN: 1bis analysis was performed using the 3,281 unique admission dataset 
classified according to "hierarchical fmal category" because the presence of a genetic 
disease in a child is used to determine the need for a genetic consultation regardless of 
whether the genetic diagnosis was related to the child's need to be hospitalized or to 
his/her hospital course. A priori, we decided that an acceptable rate for referral was 2: 
80% for categories lA, IB, IC, ID and IE, and 2: 60% for category IIA (see section 3C.5). 
Each child was cross-referenced to the PMGP database to determine if genetic services 
had ever been received. The proportion of patients in each category who had been 
referred to the provincial genetics service was determined (table 4-16). 
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Table 4-16: Clinical genetic referral rates for 3,281 unique separations analyzed 
according to "hierarchical final category". 
Hierarchical Final Number of patients Percent of patients Target referral 
Category of referred I total referred for genetic rate 
hospitalization number of patients service 
lA 20/30 66.7 > 80 
IB 90/120 75 > 80 
IC 1/7 14.3 > 80 
ID 8/10 80 > 80 
IE 51/71 71.8 > 80 
IIA 69/217 31.8 > 60 
liB 111137 8.0 
Selected cases 
IliA 60/778 7.7 (autism, 
developmental 
delay) 
liiB 27/809 3.3 -
IV 28/1063 2.6 -
v 0 I 39 0 -





SA VALIDATION STUDY: The discharge summary method of categorizing the genetic 
content of an admission was unexpectedly accurate compared with the gold standard 
geneticist interview. The accuracy for assigning one of 11 "final categories" to a 
hospitalization was 94%, with 97% accuracy for group assignment (strongly, moderately 
or weakly genetic). The narrow 95% confidence intervals for final category and group 
assignment (0.90-.97 and 0.94-0.99 respectively) indicate that the validation study had 
adequate power. 
All the discharge summaries were reviewed by a single experienced research nurse (KW) 
who received careful hands-on training by a medical geneticist prior to beginning the 
study. The training resulted in a discharge summary method that was highly accurate 
when compared to a gold standard method. All children with a final diagnosis belonging 
to group 1 were correctly assigned to group 1 by the research nurse. Within group 1, there 
was one child with multiple congenital anomalies who was labeled IE (undiagnosed 
syndrome) by the research nurse and IB (specific single-gene disorder) by the geneticist, 
however this did not change the child's overall group 1 assignment. 
The validation dataset contains a higher proportion of strongly genetic cases than the full 
study dataset (table 5-1). The sample size for the main study was calculated to ensure that 
the smallest category from previous studies was represented. This was the chromosomal 
group at ~ 1% in the two most recent larger studies (McCandles et al. 2004; Carnevale et 
al. 1985). The validation study over-represented group 1 (strongly genetic) cases by over 
2-fold. While the children used in the validation study were randomly selected, there may 
have been a bias towards the parents of children with strongly genetic conditions 
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consenting to participate (~20% of the families that were approached declined 
participation). Random stochastic effects observed with small samples are probably also 
contributing. 
TABLE 5-1: Comparison of final category group distributions between validation and 
main study datasets. 
Group 1 Group 2 Group 3 
Percentage Percentage Percentage TOTAL 
(number of (number of (number of 
cases} cases)_ cases) 
Validation study 14% 30.3% 53.7% 100% 
(gold standard) (29) (61) (111) (201) 
Main study 6.7% 25.3% 68.0% 100% 
(unique separations) (220) (829) (2232) (3,281) 
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5B THE GENETIC CONTENT OF 4,144 CONSECUTIVE PEDIATRIC 
SEPARATIONS: Tables 4-3 and 4-4 were included simply to show that most 
separations had more than one diagnosis (an average of 2.4 diagnoses per separation). 
From each diagnoses list, the one that had the highest genetic content and that was related 
to the patient's need to be hospitalized was selected, and this diagnosis was used to assign 
a "fmal category". Each diagnoses list was reanalyzed and the diagnosis with the highest 
genetic content was selected, regardless of whether it influenced the hospital stay. This 
diagnosis was used to assign each separation to a "hierarchical fmal category". The 
hierarchical classification allowed our fmdings to be compared to previous pediatric 
inpatient studies of the burden of genetic disease. 
Tables 4-5 and 4-6 summarize the distribution of the final categories for the consecutive 
admissions dataset. One of the primary research questions was determination of the 
amount of genetic disease that exists in the pediatric inpatient population. This question 
was posed because we were interested in determining the burden that children with 
strongly genetic disorders impose on the heath care system (hospitalization being one of 
the most expensive forms of healthcare ). Hence it was appropriate to use total rather than 
unique hospitalizations and "final category" (i.e. the most genetic diagnosis that was 
related to the patient's need to be hospitalized). 
The consecutive dataset contains 39 children with a chromosomal (lA) final category 
(0.94%) and 303 children with a definite (IB) or probable Mendelian (ID, IE) fmal 
category (7.4%). These two groups unequivocally require clinical genetic services (see 
section 5E.l for further discussion). Two hundred and twenty children (5.32%) had a 
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final category of IIA (heritable birth defect) for which genetic counseling or genetic 
testing is appropriate. Eight hundred and thirteen children (19.6%) had final category of 
IliA (heritable complex disease). The only diagnoses within the IliA group for which 
genetic services are presently indicated are autism and mental retardation/developmental 
delay (see sections 5E.4.1 and 5E.4.2). However over the next decade, genetic testing 
will probably be indicated for other IliA diagnoses. This testing may be used to refme 
empiric recurrence risk counseling, to predict natural history and/or to guide therapeutic 
interventions. Complex disease genetic testing of this sort is likely to be largely ordered 
by non-geneticist physicians (for further discussion see section 5E). 
Figure 5-1: Break down of 4, 144 consecutive admissions by final genetic content 
category. 
• IA=chromosomal 
• 1s, ID, IE= Mendelian 
IC=teratogen 




liB, IIIB, IV, V 
Approximately 1/3 of the children in the consecutive admission dataset had a strongly or 
moderately genetic disease, with the other 2/3 having a disease of low or minimal genetic 
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contribution (table 4-6). Our classification scheme was purposefully conservative. There 
is accumulating evidence that susceptibility to infections and to "sporadic" malignancies 
is genetically determined, but these diagnoses were classified at category IV (acquired) 
conditions. 
SB.l Comparison of the genetic content of the consecutive dataset to previous 
studies: The five earlier studies that examined the frequency and distribution of genetic 
diseases among hospitalized children all categorized the separations using the most 
genetic diagnosis regardless of whether it influenced the child's hospitalization. Hence 
the consecutive admissions dataset was reanalyzed and categorized using the 
"hierarchical final diagnosis" (table 4-7). 
The reanalysis resulted in small increases in the frequency of some of the strongly genetic 
diagnoses (e.g. lA went from 0.94% to 1 %; IB increased from 3.9% to 4.2%), however 
this resulted in only a 0.1% increase in the percent of admissions that received a group I 
or strongly genetic categorization (to 8.4% from 8.3%). The moderately genetic group 
(group 2) increased from 24.9% to 30.6% at the expense of the minimally genetic group 
(group 3), which fell from 66.8% to 61% (table 4-9). 
80 
SB.l.l Comparison of the genetic content of the consecutive dataset to previous 
studies - Limitations: Comparison of this study's frequencies to those of the earlier 
single hospital studies is limited by the following factors: 
1. The five studies are spread over almost 40 years, over which time major advances 
have been made in our understanding of the genetic etiology of disease. Moreover, some 
formerly untreatable genetic diseases are now treatable and for other genetic diseases 
there has been substantial improvement in medical and/or surgical therapeutic options. 
These medical advances may have altered the amount and distribution of genetic 
diagnoses among hospitalized children. 
The four earliest studies looked at pediatric inpatient populations from 1969-70 (Scriver 
et al. 1973), 1970 (Day and Holmes 1973), 1973 (Hall et al. 1978) and 1976-1980 
(Carnevale et al. 1985). This leaves only the McCandless dataset (sample of inpatients 
from 1996) as one that was assembled reasonably close in time to our own (2000-2001). 
By the 1970's, chromosome analysis had come into widespread use, however molecular 
genetic testing had almost no clinical utility (most of the ~2,000 genes associated with 
Mendelian diseases had not yet been identified). In spite of the testing limitations, the 
categorization of children into the broad disease categories used in all these studies 
(chromosomal, Mendelian syndrome, multifactorial birth defect etc.) would not have 
been substantially different in the 1970's compared with present day. 
For example in the mid-1960's, a multifactorial inheritance model was put forward based 
on the observation that a large number of relatively common malformations (including 
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cleft lip and neural tube defect) clustered in families without conforming to the laws of 
Mendel. The model (Carter 1965) involved the concepts of genetic susceptibility 
(conferred by multiple genes) and a threshold for expression (determined by both genetic 
and environmental factors), and remains the basis of how we think about multifactorial 
diseases today. As a second example, the first edition of one of the most widely used 
texts books of dysmorphic syndromes, Smith's Recognizable Patterns of Human 
Malformation, was published in 1970 (Jones 2006). 
However in companng hospitalized children from the 1970's to today, one could 
reasonably expect shifts in disease distribution based on the introduction of screening 
programs and improved treatment options. For example newborn screening for PKU 
allows early diagnosis so that such a child may never require inpatient care. Newborn 
screening for tyrosinemia allows long-term survival of children with a formerly fatal 
condition. Surgical advances have been made so that hypoplastic left heart and congenital 
diaphragmatic hernia are no longer fatal in the newborn period, but these children require 
significant health care resources (including long term cardiology and surgical follow up). 
2. The five earlier inpatient studies used much larger pediatric hospitals located in cities 
with populations of at least 1 million, compared to the Janeway Children's Health and 
Rehabilitation Centre which has 80 beds and is located in a city of 200,000. (table 5-3). 
The Janeway Hospital handles 60% of all the pediatric admissions for a province of just 
over 500,000 people. Even if the Newfoundland pediatric population was enriched for 
genetic diseases requiring hospitalization, this might not be reflected in a comparatively 
higher frequency of strongly genetic admissions because these larger metropolitan 
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hospitals almost certainly admitted children from outside their catchment areas who 
required complex surgeries or multidisciplinary assessments not available through the 
local hospitals. The corollary is that some types of subspecialty surgeries are not 
available at the Janeway Hospital (including cardiovascular surgery, certain high 
complexity orthopedic and urogenital surgeries) so that children requiring these would 
have a proportion of their inpatient days spent at hospitals outside the province (primarily 
the Hospital for Sick Children in Toronto, the Shriner's institute in Montreal and the 
IWK hospital in Halifax). 
3. No two of the studies used the same classification system for the genetic content of an 
admission, so that the only two categories that can be directly compared across all 
studies are the chromosomal and Mendelian groups. 
For example Scriver et al. (1973) categorized all birth defects together rather that 
separating them into ones for which there is a sibling recurrence risk (e.g. congenital 
heart disease) and those which are of lower heritability and that have a low sibling 
recurrence risk (e.g. tracheoesophageal fistula). In addition, these authors did not 
distinguish between multifactorial diseases with low heritability (e.g. cancer) and more 
"purely" environmental conditions like infections and trauma. Like Scriver's group, 
Carnevale et al. (1985) classified all birth defects together. Also, the specific diagnoses 
for low heritability complex diseases (our category IIIB) and non-genetic diseases (our 
category IV) were not listed, so we cannot be confident that the group separated these 
two categories in the same way that we did. 
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Three of the earlier studies contained enough information about the specific diagnoses in 
each category to allow the published data to be reclassified using our genetic content 
categories: Day & Homes, 1973 (see appendix C-1); Hallet al. 1978 (see appendix C-2); 
and McCandless et al. 2004 (see appendix C-3). 
The distribution across seven genetic content categories from the five earlier pediatric 
hospitalization studies and from this study is summarized in table 5-2. Table 5-3 
compares the proportion of group 1 and 2 separations (strongly and moderately genetic) 
across the six studies. 
While Hall et al. used a classification system with some differences from ours, this was 
the only earlier study which listed the majority of the specific diagnoses within each 
genetic content category, along with the frequency of the diagnoses. This allowed Hall's 
data to be reanalyzed using our genetic content categories (see appendix C-2 for details). 
In terms of making direct comparisons with our study's frequencies, the McCandless 
paper (2004) was the most challenging. While the authors listed the specific diagnoses 
within each of their broader genetic categories (IA, m, IC etc.) as an online appendix, the 
frequency with which each specific diagnosis occurred within the total number of 
hospitalizations was not reported, so that the McCandless dataset could not be reanalyzed 
using our classification scheme. 
McCandless category IA included chromosomal and Mendelian conditions, 74 and 555 
cases respectively (corresponding to our categories IA and IB). McCandless category m 
(labeled "multifactorial/polygenic diseases") contained 832 cases or 14.5% of their 
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dataset and fairly closely corresponded to our category IIA of heritable birth defects. 
However, it also included the following diagnoses which we put into group IliA (i.e 
heritable non-congenital multifactorial diseases): depression, seizures, celiac disease and 
scoliosis. McCandless category IC (labeled "heterogeneous causes, often genetic") 
contained 495 separations or 8. 7 % of their dataset. It contained a mixture of congenital 
and non-congenital disorders of both lower and higher heritability (i.e. a mixture of our 
categories IIA, liB, IliA and IIIB- see appendix C-3 for the specific diagnoses). 
McCandless category IIA ("malformations of unkown etiology") contained 48 cases or 
0.84% of their total separations. It roughly corresponded to our low heritability birth 
defects (liB), but as explained above, some of these were also included in the 
McCandless IC group. McCandless liB (19 cases) completely corresponded to our 
category IC ofteratogenic exposures. 
McCandless category III ("acquired disorders with genetic predisposition") included 
2,096 cases or 36 % of their total separations. This group was a mixture of our categories 
IliA and IIIB (i.e. high and low heritability non-congenital diseases). McCandless 
category III included all pediatric malignancies which we categorized as IIIB 
(multifactorial diseases with lower heritability). McCandless categories IV and V 
overlapped with our categories IIIB, IV and V (i.e. all conditions with low or no genetic 
contribution). 
See appendix C-3 for a more detailed breakdown of the overlap between our genetic 
content categories and those of McCandless. Suffice it to say that the conclusion from the 
analysis (summarized in table 5-2) is that the only categories that can be compared 
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between the McCandless study and the present study are the chromosomal, Mendelian 














et aL 2004* 
Present 
study 
Table 5-2: The distribution across seven genetic content categories for six pediatric 
hospitalization studies, including the present study. 
Hospital Sample Single Chrom- High Low Complex Complex 
size gene osomal heritability heritability disease disease with 
birth birth defect with sib lowRR 
defect RR 
(%) (%) (%) (%) (%) (%) 
Mas sac h . 200 4.0 0 11 21.5" 8.5 9 
General 
Hospital 
Montreal 1,089 6.9 0.4 < 18.5° < 18.5° 3.85c < 70.4° 
Children's (assumed to 
Hospital include 
malignancies) 
Children's 4,115 4.18 0.63 10.2 9.3 10.7 18.2 
Orthopedic (includes 














Janeway 4,144 7.4 1.0 7.1 4.1 23.4 27.7 
Hospital (IB, (lA) (IIA) (liB) (IliA) (IIIB) 
ID, IE) 
* see appendix C for details of how this study's dataset was reanalyzed using the genetic content 
categories from the present study. 
• 43 cases including 36 "urinary tract abnormalities", some of which we probably would have 
classified in our study as IIA (e.g. renal agenesis) or IliA (e.g. vesicoureteric reflux), but the 
break down of individual diagnoses was not given. 
b Scriver et al. did not distinguish between high heritability congenital abnormalities (e.g. 
congenital heart disease) and low heritability birth defects (e.g. tracheoeosophageal fistula). 
c In this group of 42 cases, there were 24 cases of "atopic hypersensitivity". The remaining 18 
diagnoses were not specified. 



















elncludes 101 children with an identified single-gene disorder + 50 children with multiple 
congenital anomalies (our study category IE). 
c Congenital defects were listed as broad categories (e.g. congenital heart malformations, 
gastrointestinal anomalies), so that this group could not be broken down into high and low 
heritability birth defects. 
g Includes 250 children with cancers/tumors+ 37 with "cerebral palsy and other neural system 
disorders"+ 37 with "renal disorders"+ 156 with "miscellaneous " diagnoses. 
h This group consists of 1,341 children where the diagnoses were given as broad categories, e.g. 
"infectious diseases", "gastrointestinal", "nervous system". We likely would have categorized 
some of the specific diagnoses within each broad group as Illb and others as IV. 
i Higher heritability birth defects appeared in three McCandless groups (IB,IC, ITA). The total 
number of separations in these three groups comprises 24% of their dataset, but these three 
groups also include non-congenital diagnoses and low heritability congenital anomalies. 
jLow heritability birth defects appeared in McCandless categories IC and ITA which together 
accounted for 9.44% of the dataset, but these two groups also included other diagnosis (that we 
categorized as ITA, IllA, IIIB, ID, and IE). 
k Higher heritability non-congenital multifactorial diseases appeared in three McCandless groups: 
IB (14.5% of total separations); IC (8.6% of total separations) and ill (36.5 %of total 
separations). However each of these three groups contained other diagnoses not falling within our 
iliA group. 
1 Lower heritability non-congenital multifactorial diseases appeared in McCandless categories: IC 
(8.6% of their total separations) and ill (36.5% of their total separations). Both McCandless' 
groups contained other diagnoses not falling within our lliB group. 
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Table 5-3: Comparison of frequencies across seven genetic content groups between Hall 
et al. 1978 and the present study- Chi-squared analysis. 
Genetic content Hall et al. 1978 Present study Chi-squared 
category (n=4,115) (n=4,144) 
Frequency Frequency 
(number of cases) (number of cases) 
Single-gene 4.18% 7.4% p < 0.0002 
(172) (307) 
Chromosomal 0.63% 1.0% p < 0.04 
(26) (43) 
High heritability 10.2% 7.1% p < 0.0002 
birth defect (421) (296) 
Low heritability 9.3% 4.1% p < 0.0002 
birth defect (381) (169) 
High heritability 10.7% 23.4% p < 0.0002 
complex disease (441) (971) 
Low heritability 18.2% 27.7% p < 0.0002 
complex disease (747) (1148) 
Non-genetic 46.6% 29.0% p < 0.0002 
(1916) (1202) 
Total 4,104 4,136 
[excludes 11 [excludes 8 
teratogen!IC cases] teratogen/IC cases] 
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Table 5-4: Comparison of six pediatric separation studies: type of hospital; sample size; 
method of categorization; and proportion of strongly genetic (group 1) and moderately 
genetic (group 2) hospitalizations. 
Study Type of hospital Number of separations Method of %with a 
categorization group 1* 
final 
category 
Day and Large metropolitan 200 admissions Review of "medical 4% 
Holmes university pediatric and from 20 days over the record". 
1973 adult hospital (Boston) year 1970 
(?unique) 
Scriver et al. Large metropolitan 1,089 separations Extraction of one final 7.3% 
1973 pediatric hospital randomly sampled from diagnosis by chart 
(Montreal) 12,801 admissions (July review. 
1969-July 1970) 
One of 2 pediatric 
hospitals for catchment (not unique) 
area of 2.5 million 
Hallet al. 200-bed metropolitan 4,115 separations - all Review of discharge 5.1% 
1978 pediatric university separations from sheet ( + medical chart 
hospital (Seattle); alternate months in 1973 in >50% of cases). 
Handles 55% of Assigned to a category 
admissions for metro (not unique) by most genetic 
area; diagnosis even if it did 
Total of 8,244 not influence 
admissions in 1973 hospitalization. 
Carnevale et 350-bed pediatric 2,945 separations - 1000 Review of discharge 5.95% 
al. 1985 university hospital randomly admissions sheet(+ some charts). 
(Mexico City); 7,000 from 1976, 1978 and 
admissions per year 1980 Category assigned 
(not unique) using the most genetic 
diagnosis. 
McCandless 244-bed pediatric 5,747 consecutive Review of discharge 10.8% 
et al. 2004 university (Cleveland separations - every child code -7 discharge 
OH) admitted during 1996 summary -7 full chart 
(abort only if Mendelian 
(analysis performed on or chromosomal dx 
consecutive dataset) identified). 
Category assigned 
using most genetic 
diagnosis. 
Present 80-bed pediatric 4,144 consecutive; Review of discharge 8.4% 
study university hospital (St. all separations from July codes+ discharge 
John's NL) 2000 - Sept 2001 summary (+previous 
discharge summaries) 
* group 1 final category = chromosomal or single-gene disorder 















5B.1.2 Comparison of the genetic content of the consecutive dataset to previous 
studies - Discussion: As explained above, the three categories that can be best compared 
across all six consecutive admission studies are the chromosomal, Mendelian and non-
genetic ones. 
The frequency of chromosomal disorders ranged from 0-1.29%, and so was quite 
comparable across the studies. Only the McCandless study had a chromosomal disorder 
frequency that was higher than our own (1.29% versus 1 %). Because most chromosomal 
disorders in live born infants are de novo, the incidence of these is not predicted to be 
higher in founder populations like that of Newfoundland. 
One factor that could theoretically increase the prevalence chromosomal disorders in the 
NL population is the low uptake of prenatal diagnosis among pregnant Newfoundland 
couples. Only about 25% of pregnant women in Newfoundland opt for serum screening 
for Down syndrome (comparable to most rural Canadian populations) and we know that 
the majority of woman with a fetus with prenatally diagnosed Down syndrome terminate 
the pregnancy. Lower uptake of prenatal screening could in theory lead to a higher 
proportion of children that need hospitalization because of a chromosomal disorder. 
(Cavanagh et al. 2007). 
Secondly, balanced chromosome rearrangements are found in 1 in 500 people. While 
these do not usually cause medical problems for the carrier of the translocation or 
inversion, that person is at risk of having chromosomally unbalanced offspring. Such a 
conceptus could either be miscarried or could be live born with psychomotor retardation 
and other medical problems caused by the unbalanced karyotype. Because of the large 
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sibships that were typical in Newfoundland families until this generation, a particular 
balanced rearrangement could become more common here than in a population with 
smaller family sizes. Dr. Penney Allderdice characterized one such rearrangement, a 
paracentric inversion of chromosome 3 which in the unbalanced form causes a severe 
psychomotor retardation syndrome called Allderdice syndrome. She recorded the 
outcomes of 54 pregnancies of inversion 3 carriers and 40% of these live born infants had 
unbalanced karyotypes. All the carriers of this inversion can be traced back to one 
particular NL couple (Allderdice et al. 1975; Nussbaum et al. 20012). Because of the 
severe phenotype, virtually all carriers living in this province have opted for prenatal 
diagnosis (amniocentesis) and no baby with an unbalanced karyotype related to inversion 
3 has been born in Newfoundland in over ten years (PMGP database). 
Across the six studies, the frequency of Mendelian diseases ranged from 4% to 9.5%. 
Again only the McCandless study had a higher frequency of single-gene disorders than 
our own (9.5% versus 7.4%). Our original hypothesis was that because certain Mendelian 
diseases are overrepresented in the Newfoundland founder population, this might be 
reflected in a study of hospitalized Newfoundland children. As discussed above, the 
frequencies in the Mendelian category can be reliably compared across studies. The five 
earlier studies examined admissions to large metropolitan children's hospitals serving 
admixed populations and the Mendelian frequency in our study was not strikingly 
elevated in comparison with these. 
There are a number of possible explanations. Perhaps there are over-represented 
Mendelian diseases among NL children, but these do not frequently lead to 
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hospitalization, for example syndromic and non-syndromic forms of mental retardation. 
Alternatively, the bulk of unusually common single-gene disorders in Newfoundland may 
be adult-onset conditions. Known examples include several autosomal dominant 
cardiomyopathies and hereditary cancer syndromes, including ARVD5, hereditary 
nonpolyposis colorectal cancer (HNPCC) syndrome, multiple endocrine neoplasia 
sydrome type 1 (MEN1) and hereditary diffuse gastric cancer syndrome, all of which 
only rarely manifest in children (Memer et al. 2008; Stuckless et al. 2007; Olufemi et al. 
1998; Kaurah et al. 2007). 
The McCandless study has the highest frequency of both chromosomal and Mendelian 
hospitalizations. This study's hospital was comparable to the hospitals of the other four 
earlier publications (metropolitan in location and serving an admixed population). The 
high chromosomal and Mendelian frequencies reported by this group may reflect 
availability of medical or surgical expertise at this particular hospital which led to 
admissions from outside the catchment area, i.e. enrichment for medically or surgically 
complicated children many of whom had an underlying genetic diagnosis. 
Not only were strongly genetic diseases not over-represented in our sample of 
hospitalized NL children compared with children from more admixed populations, 
neither were isolated apparently multifactorial birth defects. None of the previous studies 
divided congenital anomalies into two groups based on relative heritability, so we can 
compare only the total birth defect frequencies. In our study, 11.2 % of the admitted 
children had either a high or a low heritability birth defect. Only three of the five earlier 
studies used a classification scheme that determined the frequency of children with non-
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syndromic birth defects and these frequencies are as follows: 18.5% (Scriver et al. 1973); 
19.5% (Hallet al. 1978) and 22.4% (Carnevale et al. 1985). 
The one group of diseases that did appear to be more frequent in our dataset were non-
congenital multifactorial diseases that either have a heritability of 2: 50% or a lambda s 
2:10. These conditions include asthma, autism, type I diabetes, inflammatory bowel 
disease and juvenile rheumatoid arthritis. High heritability (non-congenital) multifactorial 
diseases were present in almost one-quarter of our consecutive admissions (23.4%), 
compared with frequencies of 8.5-10.7% in three of the earlier studies (Day and Holmes 
1973; Hallet al. 1978; Carnevale et al. 1985). Unfortunately the comparable frequency 
from the McCandless study, which is the most recent of the earlier studies, could not be 
determined. It is possible that the hospitals used in the three earlier studies had better 
resources for the outpatient treatment of chronic disease which reduced the need for 
hospitalization. Moreover the incidence of some of these IliA diagnoses, for example 
autism and asthma, has increased worldwide over the past 30 years (Persico and 
Bourgeron 2006). However the comparatively high proportion of children in our study 
admitted with a IliA diagnosis may also be due to increased disease prevalence 
attributable to Newfoundland's unique genetic architecture and/or to particular 
environmental factors acting on a genetically vulnerable background. We know for 
example that NL has one of highest incidences of type I diabetes in the world at 35 per 
100,000 per year (Newhook et al. 2008). 
The non-genetic group in our study can only be compared to two of the five earlier 




studies included children with malignancies in the non-genetic group. Hall' s list of non-
genetic diagnoses was very similar to our own (see appendix C-2) and her proportion of 
non-genetic admissions was 1.6-fold higher (46.6% versus 29%). One explanation is that 
over the almost 30 years between Hall' s study and this one, there has been a shift towards 
outpatient management of less complicated pediatric problems (a higher proportion of 
which are non-genetic, for example milder infections, fractures). Alternatively, there may 
be a true difference in the proportion of pediatric hospitalizations attributed to wholly or 
partially genetic diseases between the populations. Unfortunately, these populations 
(Newfoundland versus Seattle) were studied 30 years apart and certain multifactorial 
pediatric disease have become more prevalent over this time frame. Nevertheless, when 
compared to Hall's study, the frequencies in all the genetic categories with the exception 
of birth defects were higher in our study- see section 5B.1.3 for further discussion. 
Interesting our non-genetic separation frequency (29%) was similar to that of 
McCandless (27.2%) suggesting that the drop in this category compared to Hall' s study 
may be explained by a shift over time to handling of all but the most serious pediatric 
problems in an outpatient setting. 
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5B.1.3 Comparison of eight genetic content categories from this study's consecutive 
dataset to Hall et al. 1978: As detailed in appendix C-2, Hall's publication included 
frequencies of individual diagnoses which allowed her data to be reanalyzed using our 
classification scheme. Of the five earlier studies, this is the only one for which direct 
comparisons to our study can be made across all seven genetic content categories shown 
in table 5-2. When the two studies were compared, there was a statistically significant 
difference between six of the seven categories. Chi-squared showed a significant 
difference in frequencies for the following categories: single-gene; high heritability birth 
defects; low heritability birth defects; high heritability complex diseases; low heritability 
complex diseases; and non-genetic diseases (all p values <0.0002). 
As mentioned above, any differences between the two studies may reflect changes that 
have occurred over the past 30 years in available treatments coupled with a trend toward 
more outpatient management or, alternatively these may be indicative of true differences 
in the burden of genetic disease between the populations (or both). Also certain higher 
heritability multifactorial diseases (e.g. autism, asthma) are either more commonly 
diagnosed or have genuinely become more prevalent than in the 1970's. 
Compared with Hall's study: 
• Our total birth defect proportion is lower (11.2% versus 19.5%). 
• Our proportion of high heritability (non-congenital) multifactorial diseases is higher 
(23.4% versus 10.7%). 
• Our proportion of lower heritability (non-congenital) multifactorial diseases which 
includes pediatric malignancies is higher (27.7% versus 18.2%). 
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• Our proportion of non-genetic admissions is lower (29% versus 46.6%). 
5B.2 The most frequent Mendelian and chromosomal diagnoses for the 3,281 unique 
separations: 
5B.2.1 The commonest Mendelian Diagnoses for 3,281 unique separations: 
Approximately 6,000 Mendelian disorders have been described and about half of these 
are autosomal dominant (AD). Autosomal recessive (AR) disorders are the next most 
common accounting for about 1/3, with the most of the remainder (several hundred 
diseases) being X-linked recessive (XLR) (Nussbaum et al. 2001\ 
In our dataset, there were 120 unique separations that were assigned a hierarchical fmal 
category of IB (single-gene diseases) and of these, there were about equal numbers of 
autosomal dominant and autosomal recessive disorders (40.2% and 39.4% respectively). 
Another 3.9% of the separations were X-linked recessive. In Hall's 1978 study, among 
consecutive admissions (not unique), there was a higher proportion of autosomal 
recessive and X-linked recessive disorders than in our study: AD 29.6% (commonest 
diagnosis: Neurofibromatosis type 1); AR 56.8% (commonest diagnoses: cystic fibrosis 
and sickle cell anemia); XLR 13.5% (commonest diagnosis: hemophilia). These findings 
are consistent with the hypothesis that the a significant part of the burden of genetic 
disease in this province is due to autosomal dominant disorders which have become 
prevalent due to high sibship sizes, rather than due to AR diseases which collectively are 
still fairly rare. 
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The single commonest Mendelian disease among our 120 IB cases was also cystic 
fibrosis (17 unique cases accounting for 13.4% of the Mendelian phenotypes). CF is the 
commonest autosomal recessive disease in Caucasian children with an incidence of 1 in 
2,000 in populations of Northern European ancestry. The carrier frequency in these 
populations is high (1 in 22) and the parents of most CF patients are not consanguineous 
(Nussbaum et al. 200 14). Because of its prevalence and the fact that affected children 
frequently need hospitalization, one would expect this to be a common diagnosis among 
hospitalized children drawn from any admixed North European population. 
One of the next most common AR diagnoses was I-Cell disease (three cases). There have 
only been a few estimates of the incidence of this lysosomal storage disorder (1 in 
252,500 live births in Japan; 1 in 625,500 in the Netherlands), but it is considered to be a 
very rare disorder in most populations (Leroy 2007; Poorthuis et al. 1999). In total 19 
Newfoundland children have been diagnosed with I-cell disease (PMGP database) and all 
come from the same area on the A val on Peninsula. Two patients have been genotyped 
and both have homozygous mutations in the GNTP AB gene so this is presumably a 
founder allele. 
5B.2.2 The commonest chromosomal diagnosis for 3,281 unique separations: The 
vast majority of chromosomal abnormalities among liveborns are de novo events, so that 
one would not expect the prevalence of these to be increased in Newfoundland on the 
basis of this province' s population structure. Among our unique dataset, 43 separations 
(0.91%) received a hierarchical fmal diagnosis ofiA (chromosomal disorder) which is in 
keeping with the earlier pediatric hospitalization studies. 
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The overall incidence of chromosomal disorders in live born children is approximately 1 
in 160 (0.7%) (Nussbaum et al. 2001 5). This number does not include microdeletion 
/microduplication syndromes which were also included in our lA category. With the 
recent introduction of genomic microarray testing, we have learned that these "genomic" 
disorders are at least as common as the cytogenetic disorders identified by standard 
karyotyping (i.e. aneuploidy and structural rearrangements). This is further addressed 
below, but suffice it to say that microarray testing was not routinely ordered in 2000/2001 
when the hospitalizations in this dataset occurred. 
Of the 0.7% of liveborns with chromosomal abnormalities that can be identified with a 
standard karyotype, the commonest group of disorders are the sex chromosome 
aneuploidies which include Klinefelter syndrome (47,:XXY) and Turner syndrome. 
Numerical abnormalities of the sex chromosomes (X and Y) are found in 1 in 360 male 
births and 1 in 580 female births. Within this group, only Turner syndrome can be 
diagnosed based on clinical features either in the neonatal period or before puberty. The 
next most common group of liveborns with chromosomal abnormalities that can be 
identified on standard karyotyping are the autosomal aneuploidies (1/700 live births) and 
the commonest of these is trisomy 21 (1 /830), which is the karyotype in 95% of cases of 
Down syndrome (Nussbaum et al. 2001 5). 
Within our unique dataset of 43 lA admissions, 14 (46.7%) had Down syndrome (DS) 
which was the most frequent diagnosis, followed by two cases of Turner syndrome 
(6.7%). In the McCandless study (2004), there were 74 admissions of patients with 
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chromosomal disorders (this was a consecutive admission data set); 69% had Down 
syndrome and 2. 7% had sex chromosome abnormalities. 
About half of children with DS have at least one major congenital malformation (the 
commonest being congenital heart disease) and which often leads the child to require 
hospitalization. Moreover DS is the commonest human malformation syndrome which 
almost never goes undiagnosed, so it is not surprising that this was the commonest 
chromosomal diagnosis in the dataset. Even though the sex chromosome aneuploidies 
are commoner than DS, these are generally diagnosed later in life (sometimes not until 
adulthood when the affected individual is investigated for infertility). Moreover they are 
associated with less need for hospitalization, although some individuals require 
gonadectomy. 
Microdeletion syndromes accounted for 18/43 unique IA separations (41.9%). The two 
commonest of these were microdeletion 22q 11.2 and Angelman!Prader Willi syndromes. 
These conditions (and all the microdeletion syndromes in the dataset) can usually be 
diagnosed based on clinical features, with follow-up confirmatory fluorescent in situ 
hybridization (FISH) testing which has been routinely available since the early 1990's. 
The dataset didn't include any microduplication syndromes or any of the more recently 
delineated microdeletion syndromes that are usually diagnosed by microarray testing. 
5B.2.3 Commonest IIA diagnoses (heritable birth defect) and IliA diagnoses 
(heritable non-congenital complex disease) for 3,281 unique separations: Our 
commonest IIA diagnosis was congenital heart disease (52 I 217 IIA admissions or 24%) 
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and our commonest IliA diagnosis was asthma (302/778 IliA admissions or 38.8%). 
These were also the most common diagnoses in the comparable groups from Hall et al. 
1978: congenital heart disease accounted for 162/421 of her IIA admissions (38.4%) and 
allergy/asthma accounted for 157/441 of her IliA admissions (35.6%). We were unable to 
correct the Hall dataset for unique hospitalizations. The authors reviewed 4,115 
separations representing all hospitalizations from alternate months in 1973. 
SC IMPACT OF THE GENETIC CONTENT OF AN ADMISSION ON THE 
UTILIZATION OF HOSPITAL RESOURCES: We hypothesized that children with 
strongly genetic disorders collectively utilize more hospital resources than children with 
non-genetic conditions. Our analysis of length of stay (LOS), cumulative surgeries and 
cumulative hospital days supported this hypothesis. We divided the 4,144 consecutive 
separations into three genetic content groups for all three analyses (group 1 =strongly 
genetic; group 2=moderately genetic; group 3=minimally genetic). 
There was a statistically significant difference in mean LOS between all three groups, 
with the group 1 children having the longest mean LOS (8.01 d) and the group 3 children 
having the shortest (3.99 d). The 95% confidence intervals of groups 1 and 3 did not 
overlap (table 4-13). Hence children with chromosomal or Mendelian disorders had an 
average hospital stay that was twice as long as children with minimally genetic 
conditions. This is consistent with the findings of McCandless et al. 2004 who reviewed 
5,747 consecutive separations from 1996 to a pediatric hospital in Cleveland OH. 
Children with a single-gene or chromosomal diagnosis had an average hospital stay (7.1 
days) that was twice as long as the average stay for children admitted with infections or 
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acute trauma (3.5 d). For the categories that could be directly compared, the mean ages at 
admission also seemed comparable between the McCandless study and our own. For 
example, the mean admission ages for our chromosomal and single-gene patients were 
6.58 and 8.61 years respectively (table 4-15) and in the McCandless study, the average 
age across both groups was 7.7 years. Our average age at admission in the non-genetic 
category was 7.19 years (table 4-15) compared with 6.8 years in the McCandless study. 
In our consecutive admission dataset, there were 342 group 1 (strongly genetic) 
separations (table 4-13). About half of these (160 hospitalizations) were children with 
single-gene disorders (IB), with the other half (182 separations) being children with 
chromosomal disorders (lA) and other syndromic children where the precise genetic 
mechanism is unknown (ID, IE). See table 4-5. Within group 1, the IB children had an 
average LOS (10.57 d) that was 50% longer than that of other group 1 disorders (5.48-
5.59 d). However the longest average LOS (15.38 d) belonged to the IC separations, of 
which there were only eight (table 4-15). These are children with teratogenic exposures 
(e.g. alcohol, cocaine) where there are often social factors that necessitate hospitalization 
beyond the length of time needed for a diagnostic work up. 
In order to compare cumulative surgeries and cumulative hospital days between the three 
groups, we first calculated the total number of person years for each group. Then, we 
divided the cumulative surgeries and hospital days within each group by the number of 
person years in that group (table 4-14). 
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Cumulative surgeries per person years for groups 1, 2 and 3 respectively were as follows: 
0.302, 0.166, and 0.172. The chi-squared test gave a p-value of < 0.0001 which indicates 
that there is a significant difference between the rates of at least two groups. By 
inspection, the cumulative surgery rate between at least groups 1 (strongly genetic) and 2 
(moderately genetic) must be significant. Put another way, there were 1.8 fold more 
surgeries in the strongly genetic group than in the moderately genetic group. The number 
of surgeries was slightly higher in the moderately genetic than the minimally genetic 
group. The moderately genetic group included children with heritable birth defects (IIA) 
that often require corrective surgery, but three quarters of the group were children with 
IliA diagnoses (heritable non-congenital multifactorial diseases like asthma) most of 
which do not routinely require surgery (tables 4-5 & 4-6). The minimally genetic group 
included children with trauma which probably explains why group 3 's cumulative 
surgery rate was slightly higher than the group 2 rate. 
Cumulative hospital days per person years for groups 1, 2 and 3 respectively were: 13.61, 
3.62 and 3.55. The chi-squared test was also statistically significant (p-value < 0.0001) so 
that by inspection the rates between at least the two most divergent groups (groups 1 and 
3) must be significant. When corrected for age, group 1 children had 3.8-fold more 
hospital days than children in group 3. Hallet al. reviewed 4,115 consecutive admissions 
from alternate months in 1973 to a Seattle children's hospital and found the same trend. 
The authors looked at the average number of admissions in each of their genetic content 
groups and their "clearly genetic" group (chromosomal and Mendelian disorders) had an 
average of 5.3 admissions, more than 3-fold higher than patients with non-genetic 
disorders. However the average admission number was not corrected for age and the 
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mean age of the genetic patients (11.6 years) was significantly higher than that of the 
non-genetic group (8.6 years). 
SD ANCOV A REGRESSION MODEL: We hypothesized that pediatric patients with 
genetic diseases utilize more hospital resources than children with non-genetic conditions 
and our analysis of mean LOS, cwnulative surgeries and cwnulative hospital days across 
three genetic content groups supported this hypothesis. Moreover our LOS data were 
very comparable to the most recent previous pediatric hospitalization study (McCandless 
et al. 2004). Hence we decided to use multivariate regression to examine the impact of 
the genetic content of an admission on length of stay (LOS). We hoped to be able to 
construct a model that would use several variables (including the genetic content of the 
admission) to identify patients at risk for prolonged length of stay. 
ANCOV A was used to test the effects the following variables on LOS: final genetic 
content category; Case Mix Group code; sex; and age at admission. Because there was a 
significant interaction between two ofthe independent variables (age and final category) 
an "age x final category" interaction term was included in the model. 
In the first regression analysis, all 11 genetic content fmal categories were used (IA-V) 
and the CMG codes were analyzed as the 20 most frequent CMG codes (which accounted 
for 53.6% of the 3,281 unique separations) with the remaining admissions grouped 
together as a 21st CMG code. This model explained only 8.6% of the variance in LOS 
with 3.6% attributable to the genetic content of the admission; final genetic category 
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alone explained 2.2% of the variance and "final genetic category x age" explained 1.4% 
of the variance in LOS. 
In an attempt to improve the strength of the model, we removed the 21st "other" CMG 
category and analyzed only the 1,759 unique separations captured by the 20 most 
frequent CMG codes. This model explained 34% of the variance in LOS, but the majority 
of this (25%) was due to the CMG code, i.e. the diagnosis that led to the patient' s need to 
be hospitalized. The percent of the variance in LOS that was related to the admissions 
genetic content rose only minimally to 4.5% (final genetic category alone 1.4%; age x 
fmal category 3.1%). 
We modified the analysis a third time by simplifying the fmal genetic category variable 
as "lA or IB" (42 cases) versus "all other genetic content final categories" (1 ,717 cases). 
Only the CMG code had a significant p-value and explained 30% of the variance in LOS. 
Hence in spite of the fact that the mean LOS was significantly different over three genetic 
content groups, the bulk of the variance in length of stay in our unique admission dataset 
was determined by the admitting diagnosis, rather than by the presence or absence of a 
strongly genetic disease. For example, the above analysis suggests that the admitting 
diagnosis of pneumonia is a stronger determinant of LOS than the fact that the child has 
an underlying diagnosis of cystic fibrosis. Nevertheless from our data we can conclude 
that children with single-gene disorders (and those with teratogenic exposures) are at risk 
for prolonged lengths of stay(> 7days) (table 4-15). 
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The model did not incorporate a variable that reflects the place of residence of the child 
(for example St. John's area, the remainder of the Avalon Peninsula, outside the Avalon 
Peninsula). This factor also likely influenced LOS, with a tendency towards longer 
lengths of stay for children who live outside the St. John's area. 
5E RATES OF REFERRAL FOR CLINICAL GENETICS SERVICES AMONG 
HOSPITALIZED CIDLDREN: A priori, we decided that 80% was an acceptable 
referral rate for children with the following diagnoses anywhere in their diagnosis list: lA 
(chromosomal disorders); IB (single-gene disorders); IC (teratogenic exposures); ID 
(genetic syndromes for which the precise genetic cause has not been identified); IE 
(syndromic children with no specific syndrome identified); and IIA (heritable birth 
defects). The Provincial Medical Genetics Program's database was reviewed in 2005, so 
that any genetics referral that was initiated during a 2000 or 2001 hospitalization would 
have been captured (either as a pending or completed consultation or as an appointment 
that was not kept). 
5E.l Referral rates for children with a strongly genetic diagnosis GA. IB, ID, IE): 
The 80% referral rate was only achieved for the ID group (known genetic syndrome, but 
precise genetic etiology not identified). Eight of 10 children were referred. The diagnoses 
of the referred were: three cases of Goldenhaar syndrome; two cases of V ACTERL 
association and one case of VECS. One patient with Goldenhaar syndrome and one with 
Kabuki syndrome were not referred. These conditions are all characterized by a high 
degree of dysmorphism and/or multiple birth defects which probably explains the high 
referral rate. 
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Children who had a diagnosis that was either IB (chromosomal) or IE (multiple medical 
problems highly suggestive of a chromosomal or Mendelian disorder) also had 
reasonable referral rates of 75% and -72% respectively. 
When the individual diagnoses of the IB "referred" versus "not referred" children were 
reviewed, some trends were observed. For example, there were 24 children with inborn 
errors of metabolism and the majority (19 patients or -79%) were referred for genetic 
services. The diagnoses of the referred included Leighs disease, infantile NCL, various 
amino and organic acidopathies and storage disorders, including three cases of 1-cell 
disease. However the severity of these metabolic disorders as a group was not 
subjectively different from the diagnoses of the five metabolic cases that were not 
referred (one case of each of the following: Krabbes leukodystrophy; MERRF; 
metachromatic leukodystrophy; Pelazieus-Merzbacher disease and porphyria). Most of 
the children in the non-referred group would have presented with neurologic symptoms 
and may have been diagnosed by a pediatric neurologist. 
Within the IB group, there was a trend towards under-referral of children with Mendelian 
blood disorders. Only two of nine were referred; their diagnoses were von Willebrand 
disease (VWD) and hemophilia. The diagnoses of those not referred included three cases 
of hereditary spherocytosis, one case of G6PDH deficiency and another case of VWD. 
Hereditary blood disorders are diagnosed by hematologists, with the role of the clinical 
geneticist/ genetic counselor being limited to genetic counseling +/- confirmation of 
diagnosis by arranging molecular genetic testing. This is in contrast to most other 
Mendelian conditions (for example dysmorphic syndromes, syndromes characterized by 
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multiple birth defects and hereditary cancer syndromes) where the primary diagnosis is 
generally made by a clinical geneticist. 
There were six children with Mendelian cancer syndromes, of whom four were referred: 
two cases of familial adenomatous polyposis (F AP); one case of Li-Fraumeni syndrome; 
and one patient with multiple endocrine neoplasia type 1 (MEN1) syndrome. Two cases 
ofF AP were not referred. 
Fifteen of 17 children with cystic fibrosis (CF) were referred (~88%). Genetic testing is 
an important component of the diagnostic algorithm for a patient with symptoms 
compatible with CF and clinically relevant genotype-phenotype correlations exist. 
Eastern Health's molecular diagnostic service is organized so that (with the exception of 
testing for hereditary hemochromatosis and Factor V Leiden) all Mendelian genetic 
testing can only be ordered by one of the PMGP's clinical geneticists, which probably 
explains the high referral rate for CF patients. 
Finally within the IB group, there are several examples of diagnoses for which some 
children with that specific diagnosis were referred, whereas others were not. These 
conditions included Noonan syndrome, congenital muscular dystrophy, Factor V Leiden, 
pseudocholinesterase deficiency, and VWD. In all these cases, a general pediatrician or 
pediatric specialist could reasonably have made the diagnosis. For example, Noonan 
syndrome could be diagnosed by a pediatric cardiologist, muscular dystrophy by a 
pediatric neurologist etc. The majority of the IB children who were not referred were 
likely diagnosed by a pediatrician although some may have been diagnosed by a 
geneticist outside of the province (either as part of an external consultation that was not 
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organized by one of the PMGP's geneticists, or because the family moved to NL and had 
a genetics consultation in another province prior to relocating). 
Separations were assigned a IE diagnosis because the information contained within the 
discharge summary suggested to this study's research nurse and medical geneticist that 
the child was syndromic even though a specific syndrome was not identified. Therefore it 
is not surprising that these children had a fairly high referral rate (71 %). 
Twenty of 30 children with alA diagnosis (~67%) were referred. There was no obvious 
difference between the diagnoses of the "referred" versus the "not referred" with respect 
to disease severity. The ten cases that were not referred included chromosome disorders 
that are identified by traditional karyotyping (five cases of Down syndrome, one child 
with a ring chromosome and one with trisomy 18) and also included microdeletion 
syndromes identified by fluorescent in situ hybridization (two cases of microdeletion 
22q 11.2 and one case of Angelman syndrome). 
Down syndrome is the commonest chromosomal disorder among liveboms (as well as the 
commonest human malformation syndrome) and most pediatricians are very familiar with 
the phenotype. The American Academy of Pediatrics and others have published 
guidelines for anticipatory care of children with Down syndrome (American Academy of 
Pediatrics 2001; van Cleve and Cohen 2006). This probably explains why five of 13 
children with Down syndrome were not referred for genetic services. Moreover, within 
the Eastern Health care system, any physician can order chromosome analysis and FISH 
testing, so genetic testing within the lA group is not contingent upon making a genetic 
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referral. This is in contrast to the IB group where genetic testing cannot occur without a 
genetics referral. 
5E.2 Referral rates for children with a IC diagnosis (teratogenic exposure): There 
were seven children in the dataset with a IC diagnosis and only one (maternal HIV) was 
referred for genetic services. The non-referred included two children with fetal alcohol 
spectrum disorder, two infants of diabetic mothers and two children who were exposed to 
teratogenic medications. The referral pattern presumably reflects the fact that 
pediatricians are comfortable diagnosing these conditions. 
In 2005 Chudley et al. published guidelines for the diagnosis of fetal alcohol spectrum 
disorders (F ASD) in the Canadian Medical Association Journal. The article includes 
instructions about how to assess patients for dysmorphology typical of F ASD and was 
published in a journal with readership that is much broader than the clinical genetics 
community. It emphasizes that F ASD is a diagnosis of exclusion that cannot be 
confirmed by a specific biologic assay. F ASD has a differential that includes a number of 
genetic syndromes that cannot be easily diagnosed by a non-geneticist so that referring 
these children for a genetic consultation is of value. 
5E.3 Referral rates for children with a IIA diagnosis (high heritability birth defect): 
The second largest referral deficit occurred for hospitalized patients with a IIA diagnosis 
as the most genetic condition with the diagnosis list. A priori, we suggested that a 60% 
referral rate might be appropriate (i.e. some rate < 80% referral rate cut-off for groups lA, 
IB, IC, ID and IE where a genetic consult is essentially always indicated). This is because 
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there are some IIA diagnoses which have an appreciable sibling recurrence risk, but do 
not otherwise warrant a genetic consult. This recurrence risk should ideally be reviewed 
with the parents although not necessarily by a genetic health professional. Examples of 
such IIA diagnoses include some noncomplex forms of congenital heart disease (e.g. 
aortic stenosis and septal defects), pyloric stenosis, hypospadias and cryptorchidism. 
However even using this lower cut-off, children in the IIA group were under-referred. 
Only 69 of 217 children with high heritability birth defects ( ~ 113) were referred for 
genetic services. 
Within the IIA group of 217 unique admissions, the referral rates for some of the 
commonest diagnoses were as follows: 
1. Congenital heart disease: 6/31 were referred (19%). Within this group there were six 
children with complex congenital heart disease of whom three were referred. Because 
cardiac surgery cannot be performed at the Janeway hospital, children requiring 
surgery are referred out of the province. Hence it is possible that some children in this 
group who needed cardiac surgery were seen by a geneticist in another province. 
n. Spina bifida: 21/30 were referred (70%). Genetic consultation is indicated here to 
exclude rare syndromic causes of NTD, to review the recurrence risk for future 
pregnancies and prenatal diagnosis options, and to ensure that the mother is aware of 
the higher preconceptional folate supplementation recommendation (5 mg daily) for 
subsequent pregnancies (Wilson et al. 2007). 
iii. Cleft lip and/or palate: 18/22 were referred (82%). The high referral rate in part 
reflects the fact that these children receive outpatient medical care through the 
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Janeway's multidisciplinary craniofacial clinic and a genetic counselor from the 
PMGP is part of the craniofacial team. 
The components of a genetic consultation for a child with a IIA diagnosis include: 
1. A 3-generation pedigree, a pregnancy history to exclude teratogenic exposures, a 
medical history and examination of the child including an assessment for dysmorphic 
features. Depending on the fmdings, diagnostic imaging may be ordered to screen for 
other birth defects and to help exclude the existence of a broader genetic syndrome. 
As an example, while most clefts of the lip and palate are isolated birth defects, this 
malformation is an important feature of over 20 Mendelian and chromosomal 
disorders (Harper, 20033). If such a child is not referred for genetic services, work up 
to exclude a more strongly genetic diagnosis may be arranged by the child's general 
or subspecialty pediatrician. 
2. Genetic testing for selected cases. Examples include: FISH for microdeletion 22q 11.2 
for children with complex congenital heart disease or with cleft palates; chromosome 
analysis followed by possible single-gene testing for children with holoprosencephaly 
(HPE); molecular testing of the RET gene in a child with non-syndromic 
Hirschsprung disease; and testing for the Meunke syndrome recurrent mutation in the 
FGFR3 gene in a child with apparently non-syndromic craniosynostosis. The unique 
dataset included two children with HP E, one of whom was referred for genetic 
services and four cases of Hirschsprung disease none of whom were referred. 
3. Based in the fmdings in steps 1 and 2, recurrence risk counseling. Assuming that a 
broader syndrome is not identified, the parents of a child with a IIA isolated birth 
112 
defect have an empiric risk of having another affected child of 2-1 0% depending on 
the birth defect (Harper, 20032). 
The negative repercussions of not referring a child with a ITA diagnosis include: 
1. Potentially misclassifying a birth defect as isolated when it is a feature of a broader 
genetic syndrome. If a child with an apparently isolated birth defect is carefully 
reviewed by a pediatrician this is unlikely to occur. While a pediatrician may not be 
able to provide a specific syndromic diagnosis, he or she is likely to be able to 
identify that the child's phenotype puts the patient into a syndromic category. 
Nevertheless, non-referral could in some instances result in failure to recognize that 
the child has a broader syndrome, in which case the child may lose the benefit of 
early medical or surgical interventions. For example if a boy with unilateral renal 
agenesis is classified as having an isolated birth defect, but actually has Branchio-
Oto-Renal (BOR) syndrome, he probably will not receive audiology screening 
(beyond the routine newborn screening) until his preschool health check. In this 
scenario, there may be delayed diagnosis of a hearing loss that is not present at birth, 
but that impacts speech and language acquisition. 
Similarly if an apparently isolated cleft palate is actually part of microdeletion 
22q 11.2 syndrome, the child will not be evaluated for ectopically placed carotids and 
may suffer an adverse outcome during palate repair. In his textbook Practical Genetic 
counseling, Peter Harper states ''few cases ... (of microdeletion 22qll) ... are truly 
non-syndromal, but the features can be subtle" (Harper, 20034). Other baseline 
investigations that should be arranged once microdeletion 22q is diagnosed include: 
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calcium studies; absolute lymphocyte count and evaluation of the humoral immune 
system; and renal ultrasound. Furthermore, a person with microdeletion 22q 11 should 
have a speech and language assessment by age 1 year because almost all affected 
individuals have delayed speech and benefit from early language intervention 
(McDonald-McGinn et al. 2005). 
2. Failure to arrange genetic testing. The most common genetic tests indicated for 
children with a IIA diagnosis are chromosome analysis and FISH testing (to rule out a 
chromosomal syndromic etiology). These tests can be ordered by a non-geneticist as 
long as that physician recognizes that such testing is indicated. However there are 
instances where a specific molecular genetic test should be ordered, as described 
above. 
Over the next decade, molecular genetic testing for isolated birth defects will almost 
certainly be incorporated into clinical practice. There are two categories of future 
clinically relevant genetic tests for birth defects: 
a) Tests for a panel of alleles (gene variants and or copy number variants) that have 
been identified as determining the genetic risk for a multifactorial malformation. 
Before such "DNA chips" can have clinical utility, the malformation's underlying 
genetic etiology must be fully understood, and this is likely to include multiple 
susceptibility and protective alleles. 
b) Tests for particular single-genes which when mutated produce a Mendelian form of 
an isolated birth defect. 
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At present only a handful of susceptibility genes for multifactorial congenital 
malformations have been identified. For example the MI'HFR 677C->T allele was the 
first recognized genetic risk factor for folate-sensitive neural tube defects (NTDs ). 
Fetal homozygosity for this allele is associated with up to a 7-fold increased risk of 
NTD in certain populations (Ou et al. 1996). Because any one such susceptibility 
gene confers only part of the genetic risk, these tests are not yet being offered 
clinically. Once the susceptibility and protective alleles for a particular multifactorial 
genetic disorder have been identified, probands and their parents can be genotyped 
for high and low risk markers. The algorithm for refining recurrence risk based on 
parental genotype will also need to include "gene x environment" interactions. 
Genes that operate in a Mendelian way to produce isolated birth defects have been 
identified. Due to the rarity of such cases, these molecular tests are not in wide spread 
clinical use, although some examples were mentioned above. As the price of 
molecular genetic testing falls (Chung 2007), this situation is likely to change. Other 
examples of isolated malformations caused by single-gene mutations include: 
1. CFCJ: In 2002, Goldmuntz et al. showed that autosomal dominant CFCJ 
mutations cause not only heterotaxy syndromes, but in rare instances isolated 
complex congenital heart disease (transposition of the great arteries and double 
outlet right ventricle). Most patients have de novo mutations, but recurrence could 
occur if one parent had gonadal mosaicism for the mutation. A couple who have 
had a child with a CFCJ mutation would have the option of prenatal molecular 
genetic testing in subsequent pregnancies. 
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u. Similarly several genes have been identified that cause isolated autosomal 
dominant cleft lip and/or palate including MSXJ (Jezewski et al. 2003), IRF6 
(Kondo et al. 2002), TP63 (Leoyklang et al. 2006) and SUMO 1 (Alkuraya et al. 
2006). Only IRF6 testing is clinically available (www.genetests.org). A patient 
with a bilateral cleft lip and palate who has an IRF6 mutation has a 50% risk of 
having an affected child (rather than the multifactorial offspring recurrence risk of 
5-6%). 
For cleft lip and palate patients, pedigree review is important not only because it 
may identify an autosomal dominant family history of clefts, but also because it 
may reveal a cancer pattern suggestive of the presence of an E-cadherin mutation. 
Autosomal dominant mutations in this gene cause Hereditary Diffuse Gastric 
Cancer (HDGC) syndrome. The hallmark malignancies are diffuse gastric cancer 
and lobular breast cancer, but cleft lip with or without cleft palate is also a feature 
(Frebourg et al. 2006) and this is the only manifestation of the syndrome that 
would be present in a mutation-positive child. HDGC is over-represented in 
Newfoundland due to the presence of a E-Cadherin founder mutation (see section 
2B.3) 
3. In the absence of a genetics consultation, the parents of a child with a IIA birth defect 
may not be counseled about their risk of having another affected child and may fail to 
be referred to a maternal fetal medicine specialist (high-risk obstetrician) during 
subsequent pregnancies. 
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As an example, all children with holoprosencephaly (HPE) should have a 
chromosome analysis. 25-50% have a chromosome abnormality with specific 
recurrence risk figures depending on the abnormality. Another 5% have 
microdeletions which are usually de novo and associated with a low recurrence risk. 
These can be identified through genomic microarray analysis, and in most Canadian 
centres microarray testing can only be ordered by a clinical geneticist. If the above are 
both normal and the child appears to have a non-syndromic form of HPE, testing of 
the following autosomal dominant genes should be considered: SHH, TGIF, SIX3 and 
ZIC2. These genes cause Mendelian non-syndromic forms of HPE and are associated 
with strikingly variable phenotypes even within families, ranging from alobar HPE to 
essentially normal individuals who have ocular hypotelorism (closely spaced eyes). If 
a mutation in one of these genes is identified and one of the parents is a carrier, the 
recurrence risk for subsequent pregnancies is 50% (Meunke and Gropman 2005). 
5E.4 Referral rates for children with a IliA diagnosis: The IliA diagnoses are 
multifactorial diseases with high heritability, excluding birth defects. 778 children in the 
dataset had a IliA diagnosis of whom 60 were referred ( ~8% ). 
Genetic referral is appropriate for a subset of children with a IliA diagnosis (e.g. autism 
spectrum disorder, mental retardation), but in the absence of a Mendelian looking family 
history, referral is not indicated for most of these conditions (e.g. diabetes, asthma, 
inflammatory bowel disease). There is also a group of IliA diagnoses for which referral 
to genetics may be appropriate (ADHD, behavioral abnormalities, seizures, some 
psychiatric conditions including schizophrenia). 
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In our dataset, the two most common IliA diagnoses for which genetic consultation is 
indicated are autism spectrum disorder (ASD) (Chudley et al. 1998; Battaglia and Carey 
2006; Schaefer and Mendelson 2008) and mental retardation/developmental delay (Fryns 
et al. 1986). 
5E.4.1 Referral rates for children with a IliA diagnosis - Autism: Within the IliA 
group, there were 16 autistic children of whom 10 were referred (64%). Every autistic 
child should ideally be assessed by a medical geneticist; about 25% have significant 
dysmorphology and in up to half of these, the physical findings lead to a syndromic 
diagnosis (Miles et al. 2005). Each affected child should have routine chromosome 
analysis and DNA testing for Fragile X syndrome (FMR1 gene), with diagnostic yields of 
5-10% and 5% respectively (Miles and McCathem 2005; Reddy 2005; Schaefer and 
Mendelsohn 2008). If the child tests positive for an FMR1 mutation, his or her parents 
have a 25% risk of having a son with Fragile X syndrome and prenatal diagnosis is 
available. 
Admittedly the following information about the genetic etiology of autism was not 
known during the 2000-2001 period over which the study children were hospitalized, 
however our improved understanding of the genetics of ASD underscores the importance 
of a clinical genetics consultation: 
1. Firstly, recent publications recommend that genomic microarray analysis be 
considered for any autistic child if the above routine genetic blood work is normal 
(Marshall et al. 2008). The microarray screens the genome for dosage imbalances and 
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is one method of identifying copy number variants (CNVs) at the 16p11.2 locus. 
Microdeletions and microduplications at this locus occur in 1% of autistic children 
(Marshall et al. 2008; Weiss et al. 2008). This CNV is usually a de novo change so 
the parents of a child with a 16p 11.2 CNV have a recurrence risk that is less than the 
5-10% empiric sibling recurrence risk for "multifactorial" autism. This lower 
recurrence risk may influence the parents' decision about having more children. 
u. Secondly, several Mendelian forms of ASD have been recognized and genetic testing 
for these is indicated in selected cases. Examples include neuro/igin-3 and 
neuroligin-4 testing in patients with an X-linked family history and PTEN testing in 
autistic children with macrocephaly greater than 4 standard deviations above the 
mean. (Miles and McCathem 2005; Jamain et al. 2003; Laumonnier et al. 2004; 
Butler et al. 2005). Any individual with a PTEN mutation is believed to be at 
increased risk for developing Cowden syndrome related malignancies and cancer 
screening is recommended beginning at age 18 (Zbuk et al. 2006). 
Schaefer and Mendelsohn (2008) made the strongest published recommendation to date 
for referring autistic patients to a clinical geneticist. The authors propose a three tiered 
clinical genetics evaluation and suggest that it will have an overall diagnostic yield of 
40%. The first tier includes: dysmorphology and Woods lamp examinations (the latter for 
pigmentary abnormalities of the skin); chromosome analysis; and DNA testing for 
Fragile X syndrome. The second tier includes genomic microarray, with the following 
additional tests targeted to specific patient subsets: skin karyotype for patients with 
significant pigmentary abnormalities; sequencing of the MECP2 gene for all female ASD 
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patients; and PTEN testing for individuals with a head circumference >+2.5SD. Tier 3 
investigations include brain MRI and methylation analysis of chromosome 15. 
The authors emphasize that recent advances have created the opportunity for clinical 
geneticists to move from empiric recurrence risk counseling to diagnosis-related 
counseling for patients with autism. 
5E.4.2 Referral rates for children with a IliA diagnosis - mental retardation (MR): 
Within the IliA group, there were 59 children with mental retardation/developmental 
delay of whom 18 were referred (31%). 
Bodensteiner and Schafer (1995) state that the "association of mental retardation and 
congenital malformations has long been recognized" and that "a necessary component of 
the evaluation of the child with idiopathic mental retardation is a comprehensive 
dysmorphologic examination. " The literature suggests up to 50% of individuals with MR. 
have an identifiable etiology. Once environmental causes have been excluded, the 
dysmorphology examination is used to categorize the patient as having syndromic or non-
syndromic MR. Any child with delayed speech, language or motor development of 
unknown etiology should have a chromosome analysis and DNA testing for Fragile X 
syndrome. Other targeted investigations include metabolic testing, brain MRI, genomic 
microarray analysis and confirmation of suspected specific syndromic forms of MR. by 
molecular genetic testing (Firth and Hurst 2005; Curry et al. 1997). In the future, DNA 
chips will probably be used to test multiple MR. genes simultaneously. 
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5E.4.3 Referral rates for children with other IDA diagnoses: Within the unique 
dataset of 778 children with a IliA diagnosis, there were some specific diagnoses for 
which genetic referral may be indicated depending on the presence of other clinical 
features and/or a positive family history. The referral patterns for some of these include: 
1. ADHD and/or behavioral abnormalities: 10/52 (19.2%) were referred. 
n. Non-febrile seizures: 8/82 were referred (9.8%). There were two cases of infantile 
spasms and both were not referred. Infantile spasms develop in up to 113 of children 
with tuberous sclerosis which is an autosomal dominant disease (Curatolo et al. 
2008). 
iii. Psychiatric disorders: 3/78 referred. The diagnoses of the three patients that were 
referred were: depression, bipolar disorder with autism, and obsessive compulsive 
disorder with autism. 
5E.5 Deficits in genetic consultations vs. existing clinical genetic resources: During a 
14-month period, 3,281 unique hospitalizations generated 365 genetic consultations (~9% 
of all the hospitalizations). Although data on the timing and location of these 
consultations was not extracted, it is reasonable to assume that these occurred as a 
mixture of inpatient and outpatient assessments, and that these consults could have 
occurred either before, during or after the index hospitalization. The dataset contains 
another 129 children who had a diagnosis that was an unequivocal indication for genetic 
referral, but who were not referred. This number was calculated assuming that all IA-IE 
children and that 60% of IIA children should have been referred. Children with a IliA 
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diagnosis of either developmental delay or autism were also included as shown in the 
following table (table 5-5). 
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Table 5-5: Children with a final genetic category that was an indication for genetic 
consultation who were not referred for genetic services: 
Category Number of children 








Selected IliA 41 DD +6ASD 
TOTAL 129 
Assuming that none of these 129 children had a genetic consult outside the province that 
was not evident in the discharge summary, the total number of referred cases should have 
been 365 + 129, i.e. 494/ 3281 or 15.1% of the unique dataset. Put another way, for 
almost every three children that were referred, there was one child who was 
inappropriately not referred. 
Taking this one step further, assuming that 1999/2000 referral pattern is similar to the 
present one, there is a genetic referral deficit of 129 children over an 14-month period or 
111 children annually. 
Although the PMGP is part of Eastern Health, it has a provincial mandate to deliver 
genetic services. Present staff includes two clinical geneticists and eight genetic 
counselors (GC's), including two GC's that work in outreach clinics in Gander and 
Comer Brook. The physicians see all the referred patients who do not yet have a specific 
genetic diagnosis; many of these individuals require a physical examination. The genetic 
counselors have relatively independent caseloads of patients with known genetic 
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diagnoses who require genetic counseling and/or genetic testing. Almost all of the 
"inappropriately not referred" children described above would have required a physician 
rather than genetic counselor assessment. 
During the 2005-2006 fiscal year, 1,621 patients were referred to the PMGP and 1,805 
patients were seen by a clinical geneticist and/or a genetic counselor. The distribution of 
the types of consults was: 15% prenatal; 40% pediatric; and 45% non-prenatal adult 
cases. 88 of the 1,805 consultations were inpatient consults which were done by one of 
the clinical geneticists, and over 90% of these were neonatal or pediatric cases. The two 
clinical geneticists each saw ~400 patients (i.e. a total of 800 patients including the 88 
inpatient consults). The remaining 1,000 cases were seen by a genetic counselor and 
supervised and then co-signed by one of the two clinical geneticists. 
The present wait time for semi-urgent and non-urgent patients to see a clinical geneticist 
is six months and two years respectively. In order to accommodate the non-referred 
children without increasing the present wait time, each of the clinical geneticists would 
have to assess ~12.5% more patients per year (an additional ~50 patients annually, 
representing 1.5 extra month's worth of patients). 
5E.6 Future of genetic testing for complex diseases and the role of medical 
geneticists/genetic counselors: The Human Genome Project was a 13-year international 
effort that was coordinated by the US Department of Energy and the National Institute of 
Health, and one of its major goals was to sequence the entire human genome. This was 
achieved in 2003 when 95% of the gene containing part of the human genome was 
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finished to 99.99% accuracy (Collins et al. 2003). The genome is estimated to contain 
25,000 genes over 2,100 of which are associated with a monogenic human disease. 
Clinical genetic tests are available for >1100 disorders (www.Genetests.org). These 
phenotypes are within the traditional realm of clinical geneticists and genetic counselors. 
Completion of the human sequence, coupled with sequencing of the genomes of several 
important model organisms (including yeast and drosophila) and characterization of the 
human haplotype structure, provided the tools necessary for large scale genome-wide 
association studies. These have started to identify genes that harbor variations which are 
associated with common multifactorial diseases. Examples that are relevant to the 
pediatric population include type I diabetes, obesity (Frayling et al. 2007), inflammatory 
bowel disease (Duerr et al. 2006; Duerr 2007) and autism (Losh et al. 2008). 
Another previously undetected source of variation in the genome is differences in the 
copy number of genes. Copy number variants (CNVs) are detected by genome 
microarrays and appear to underlie a significant fraction of birth defects, mental 
retardation and autism. It has been hypothesized that CNV s also increase susceptibility to 
other more common psychiatric and medical conditions (Fernandez et al. 2009; Cook and 
Scherer 2008; Shaffer and Bejjani 2006; Zahir and Friedman 2007). 
Numerous reviews and editorial articles have been published which discuss the fact that 
we are about to enter the era of "molecular medicine" (Chung 2007; Woodcock 2007; 
Sieberts and Schadt 2007). Individual genetic and genomic information will almost 
certainly be integrated into health care provision and will be increasingly utilized in every 
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field of medicine. Treatment will become targeted less by symptoms and more by 
understanding the fundamental causes of disease, and it has been predicted that future 
drug design will be based on knowledge of perturbed genes. 
The potential benefits of molecular medicine include: 
1. Refming the treatment of common diseases. An individual's genetic variations may 
used to select a particular drug and/or to determine dosing (see section 5E. 7 for 
further discussion). 
2. Preventing disease by identifying genetic variants that make certain individuals 
susceptible to an adverse outcome from a particular environmental factor (e.g. lung 
cancer from smoking). Similarly, individuals with particular genotypes may benefit 
from a preventive medical therapy or increased surveillance. This may occur through 
population screening. 
That being said, it is clear that the genetic basis for most common diseases is complex 
involving multiple genetic variants (gene polymorphisms and possibly copy number 
variants) and interactions with the environment. Algorithms for predicting the 
development of common diseases will not come into clinical use until all the genetic 
determinants of a disease have been identified (both susceptibility and protective 
variants). Also "gene x gene" and "gene x environment" interactions must be factored in 
to the composite risk calculation. To date, there is no complex disease for which the 
underlying genetics is this completely understood. 
Currently, genetic medicine is delivered by physician specialist medicaVclinical 
geneticists and masters trained genetic counselors. In Canada, there are 106 practicing 
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medical geneticists who have been certified through the Royal College of Physicians and 
Surgeons and/or the Canadian College of Medical Geneticists (personal communication, 
Roberta Sulpha, CCMG secretariat, 2008). There are ~250 genetic counselors certified 
through the Canadian Association of Genetic Counsellors (CAGC) who are employed in 
Canada. 
There is agreement in the literature and within the Canadian clinical genetics community 
that once genetic testing for common complex diseases becomes part of routine medical 
practice, the volume of such genetic testing will rapidly overwhelm traditional genetic 
clinics. These tests will almost certainly be ordered by family physicians and non-
geneticist specialists who will use the tests to make clinical decisions. Some individuals 
who have had genetic testing for complex diseases may be flagged for referral for genetic 
counseling. The genetic counselor who provides this may work in a traditional genetics 
clinic. Alternatively, the counselor may work in a subspecialty clinic or may be under the 
supervision of a diagnostic laboratory director. 
Assuming complex disease testing becomes part of the general practice of medicine, the 
following is a breakdown of children from our dataset who would require genetic 
services (table 5. 6). 
We have assumed that no child within the liB, IIIB, IV or V group would require genetic 
services (clearly not the case because some of these children were referred). The 
calculation used the simplified assumption that all IA-IE children require genetic 
consultation that would be provided by a clinical geneticist working with the assistance 
of a genetic counselor. We assumed that 60% of the IIA group would require the same, 
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with the rest of the group being eligible for complex trait genetic testing that would be 
organized outside a traditional genetics clinic. Most of the IliA group (with diagnoses 
that include Type I diabetes and other autoimmune diseases, most psychiatric disorders 
and inflammatory bowel disease) would have the option of complex disease genetic 
testing ordered by a non-geneticist physician, and only the MRI developmental delay and 




Table 5-6: Breakdown of patients from the unique admissions dataset (3,281 patients) 
who will require genetic services once complex disease genetic testing is routinely 
available. 
Hierarchical Final Number of patients Number to be seen Number to 
Category of by a clinical receive genetic 
hospitalization geneticist services outside 
~enetics clinic 
lA 30 30 -
IB 120 120 -
IC 7 7 
ID 10 10 -
IE 71 71 -
IIA 217 130 87 
liB 137 - -
IliA 778 *75 703 
IIIB 809 - -
IV 1,063 - -
v 39 - -
TOTAL 3,281 443 790 
*there were 16 unique patients with autism and 59 with mental retardation or 
developmental delay 
The above table shows that within the dataset of 3,281 unique hospitalizations over a 14-
month period, 13.5% presently require genetic services from a clinical geneticist and 
another 24% are likely to eventually require complex disease genetic testing through a 
non-geneticist physician. 
The model has not addressed pharmacogenomic testing which may be relevant to many 
of the category IV children. 
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5E.7 Pharmacogenomics: Phannacogenomics refers to the concept of screening for 
genetic variants that determine drug metabolism and adverse drug effects. Differences in 
drug metabolism have been linked to genes that encode drug metabolism enzymes, drug 
transporters and drug targets. The goal of phannacogenomics is to avoid the trial and 
error approach to drug therapy by screening patients for such variants. The patient's 
genetic profile will be used to select the "best drug" at the "best dose". This approach 
will improve the efficacy of prescribed medications and reduce side effects, which should 
in turn increase patient compliance. At present between 20-40% of patients fail to 
respond to commonly used medications for diabetes, hypertension and depression (Haga 
and Burk 2004). 
Unlike genetic testing for multifactorial diseases, which presently has limited clinical 
utility, some phannacogenomic tests are being ordered by physicians for patient 
management. As an example, the enzyme thiopurine methyltransferase (TMPT) 
inactivates thiopurine drugs like azathioprine, thioguanine and 6-mercatopurine. These 
drugs are used to treat patients with conditions that include inflammatory bowel disease, 
rheumatoid arthritis, acute lymphoblastic leukemia and organ transplant rejection. One in 
300 people is homozygous for a variant that encodes a form of the enzyme with reduced 
activity. When such a person is given a thiopurine drug, the active compound 
accumulates leading to potentially fatal bone marrow failure. Some physicians now 
screen for this variant prior to administration of a thiopurine drug and administer a lower 
dose if the patient carries two copies of the variant. It is worth noting that any siblings of 
such a patient are at 25% risk of having the same genotype and should be counseled 
accordingly (Zhou 2006; Firooz et al. 2008; Tsui 2008). 
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Cytochrome p450 is a complex of heme containing enzymes. Two of these genes, 
CYP2D6 and CYP2CJ9 are responsible for the metabolism of 25% of drugs. Roche 
diagnostics has marketed the AmpliChip CYP450 test. The chip assays 31 variants in 
these two genes and the results are integrated to produce a simple interpretation - the 
patient is predicted to be a poor, intermediate, extensive or ultrarapid metabolizer (Chung 
2007). As the field of pharmacogenomics moves forward, it is easy to imagine that a 
substantial proportion of patients who are prescribed a medication might have a genetic 
test so that they can be dosed according to their drug metabolizing phenotype. Hence 
many of the category IV children (table 5-5) might also have been candidates for 
molecular genetic testing if screening for variation in drug metabolism was part of the 
routine practice of medicine. 
SF. STRENGTHS AND LIMITATIONS OF THE STUDY: 
SF.l Strengths: One of the strengths ofthis study is the large number of hospitalizations 
that were reviewed, 4,144 consecutive separations over a 14-month period to the only 
tertiary-level pediatric hospital in Newfoundland and Labrador. The method of 
determining the genetic content of each hospitalization (review by a research nurse of the 
ICD-9 discharge codes, of the index discharge summary and of up to two previous 
discharge summaries if these existed) was validated against a gold standard (review of 
patient and medical record by a clinical geneticist) and was shown to be highly accurate. 
None of the previous pediatric admission studies included a ~alidation component. The 
sample size was comparable to the Hall (1978) and McCandless (2004) publications and 
gives excellent statistical strength to the findings. 
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While all the previous pediatric hospitalizations studies clearly identified children with 
strongly genetic conditions (chromosomal and Mendelian diseases), our classification 
scheme of multifactorial conditions was unique and we believe more meaningful than the 
various earlier approaches. We divided multifactorial conditions into birth defects versus 
non-congenital disorders, and further subdivided each into high and low genetic content 
groups based on heritability and/or on the sibling recurrence risk (As) for each disorder. 
Another unique feature of our study is that the sample was drawn from a founder 
population. Because Newfoundland has been recognized as one of a handful of founder 
populations, the amount and distribution of genetic disease in this province may be 
different than in more admixed populations. This is the first Newfoundland study that has 
attempted to quantitate the burden of genetic disease using, as a sample of convenience, 
inpatients from the only pediatric hospital in the province. 
Our analysis of hospital utilization data was more comprehensive than any of the 
previous studies, most of which were limited to mean length of stay (we also examined 
cumulative hospital days and cumulative surgeries). 
Finally apart from Scriver et al. 1973, ours is the only study that examined the clinical 
genetic referral rates for children with strongly genetic diagnoses (and with particular 
moderately genetic diagnoses). 
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5F.2 Limtations: The validation study was performed using only one medical geneticist, 
with no inter-observer reliability estimate. 
In the main study, we examined the burden of genetic disease among hospitalized 
children primarily by determining the prevalence of particular categories of disease. We 
examined disease severity only indirectly, by looking at differences in utilization of 
hospital resources between different genetic content groups. 
Our ability to classify the genetic content of each admission was limited by the conditions 
that were recognized and written down by the admitting health care team. Although the 
method of categorizing the separations was validated, it was retrospective. Also we 
somewhat arbitrarily divided multifactorial diseases into two groups based on either 
sibling recurrence risk (with a cut-off of 1 0) or heritability estimate (with a cut-off of 
50%). 
Our ability to accurately classify the hospitalizations was also limited by our current 
understanding of the genetic basis of the disorders. In particular, it may turn out that a 
proportion of certain diseases that are presumed to be multifactorial are in fact strongly 
genetically determined. As an example, while many children with non-syndromic mental 
retardation have multifactorial MR, some have single-gene forms or pathogenic copy 
number variants (CNVs). Identification of the former group is still hampered by the cost 
of genetic testing. Microarray testing identifies the latter. While microarrays are now 
routinely ordered by clinical geneticists, none of the children in the dataset would have 
had this test. Among the MR population with a normal routine karyotype, genomic 
microarray testing identifies a pathogenic genomic deletion or duplication in 10-15% 
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(Stankiewicz and Beaudet, 2007). In this study, children with MR were classified as 
having a group 2 or moderately genetic disorder. If all of these had been referred for 
genetic consultation and if microarray testing had been in routine clinical use (as it now 
is), up to 15% of these children would have been categorized to the strongly genetic 
group (group 1 ). 
Another limitation is that the study is not truly population-based. While 60% of 
Newfoundland children who need hospitalization are admitted to the Janeway hospital, 
the rest are admitted to community hospitals throughout the province. Because many of 
these hospitals do not have computerized discharge summaries, these children were 
excluded from the study. Because the Janeway hospital is the only pediatric hospital in 
the province, some referral bias also exists. Sicker and more medically complicated 
children are more likely to be admitted to the Janeway hospital even if there is a local 
community hospital that accepts children. 
Also this study did not include neonates either born in the hospital or admitted to the 
neonatal intensive care unit. The objective of the study was to examine the genetic 
disease present among patients admitted to hospital, so that newborns born in the hospital 
and admitted to the nursery as part of routine care were excluded. We agree with 
McCandless et al. (2004) that the neonatal intensive care unit population warrants its own 
study, with classification criteria specifically designed for them. This population is likely 
to contain a higher proportion of patients with strongly genetic disorders and birth 
defects. Some of these probably have such severe phenotypes that they do not survive the 
neonatal period and hence would not be seen in a pediatric inpatient sample. 
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SG CONCLUSIONS: Newfoundland has been recognized as one of the world' s 
relatively few "very young" founder populations. Due to genetic drift and founder effect, 
certain Mendelian diseases are more common in this province than in outbred 
populations, with many of the documented examples being adult-onset disorders. This is 
the first study that attempted to quantitate the net burden of genetic disease in 
Newfoundland, using as a sample of convenience 4,144 consecutive pediatric admissions 
to the only tertiary-level children's hospital in this province. 
We validated our study methods (retrospective determination of the genetic content of an 
admission through review of discharge codes and discharge summaries) against a gold 
standard (review of the patient and hospital chart by a medical geneticist). We found that 
the retrospective review had a high level of accuracy, presumably because each 
separation' s discharge summary was carefully reviewed by a single research nurse rather 
than relying on discharge codes alone to categorize the separations. 
Our dataset consisted of 4,144 consecutive children (neonates were excluded) who were 
hospitalized over a 14-month period in 2000 and 2001. We found that 7.32% were 
admitted because of a Mendelian or probable Mendelian genetic syndrome (303 children) 
and that -1% were admitted because of a chromosomal disorder (39 children). Hence 
diseases that are entirely (or nearly entirely) genetically determined were responsible for 
8.3% of the consecutive hospitalizations. Children with higher heritability multifactorial 
diseases (birth defects and diseases that are not congenital) accounted for -25% of the 
dataset (1,033 admissions). The remaining two-thirds of the admissions occurred because 
of a minimally or non-genetic condition. 
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There have been five previous studies of the burden of genetic disease among children 
admitted to a single pediatric hospital. In order to make our data more comparable to that 
of the earlier studies, each separation's diagnosis list was reanalyzed and the 
hospitalization was assigned to a genetic content category (the hierarchical final 
category) based on the diagnosis that had the highest genetic ranking, even if it did not 
contribute to the child's need to be hospitalized or influence the hospital stay. 8.4% of the 
admitted children had a strongly genetic diagnosis (7.4% single-gene and 1% 
chromosomal) and 30.6% had a moderately genetic disease. The frequency range for 
Mendelian and chromosomal diseases in the earlier studies was 4-9.5% and 0-1.29% 
respectively (table 5-2). Hence our initial hypothesis was not correct; the proportion of 
hospitalized NL children with strongly genetic diseases was not higher than previously 
documented in admixed populations. Most of the founder effect mutations that have been 
identified in the Newfoundland population are adult-onset diseases (HNPCC, ARVD5, 
MEN1 etc). Hence while there may be some over-represented Mendelian diseases that 
affect children (a known example is infantile neuronal ceroid lipofuscinosis), when 
aggregated as a group and compared to previous single hospital studies, single-gene 
disorders do not appear to disproportionately burdening Newfoundland's pediatric 
inpatient services. 
Moreover our dataset contained a lower proportion of Newfoundland children with 
apparently multifactorial birth defects than any of the five earlier studies (table 5-2). 
None of the previous studies divided congenital anomalies into two groups based on 
sibling recurrence risk, so we can compare only the total birth defect frequencies. In our 
study, 11.2 % of the children had either a high or a low heritability birth defect. Only 
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three of the five earlier studies used a classification scheme that determined the frequency 
of children with non-syndromic birth defects which ranged from 18.5%- 22.4% (Scriver 
et al. 1973; Hallet al. 1978; Carnevale et al. 1985). 
Compared with earlier publications, conditions that were more common in our 
consecutive admission dataset were the group of higher heritability multifactorial 
diseases (excluding birth defects). These diseases include asthma, autism, type I diabetes, 
inflammatory bowel disease and juvenile rheumatoid arthritis (JRA). These IliA 
multifactorial diseases were present in almost one-quarter of our consecutive admissions 
(23.4%), compared with frequencies of 8.5-10.7% in three of the earlier studies (Day and 
Holmes 1973; Hall et al. 1978; Carnevale et al. 1985). Unfortunately the comparable 
proportion from McCandless' 2004 study, which is the most recent of the earlier studies, 
could not be determined. While some of these diseases have become more prevalent 
worldwide over the past 30 years, it is possible that a subset (for example type I diabetes) 
is over-represented in our province because of the population's genetic architecture, i.e. 
because of drift of disease-associated alleles in the Newfoundland population compared 
with the parental Irish and English populations. 
Our study sample included 120 unique children who were hospitalized with a single-gene 
disorder, and roughly equal numbers had an autosomal dominant disease versus an 
autosomal recessive one (40.2% and 39.4% respectively). The proportion ofNL children 
with autosomal recessive disorders was lower than in Hall' s study (1978) where 56.8% of 
the children with Mendelian disorders had an autosomal recessive disease. This finding is 
consistent with the hypothesis that much of the burden of genetic disease in this province 
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is due to autosomal dominant disorders which have become prevalent due to large 
numbers of families with high sibship sizes, rather than due to autosomal recessive 
disorders which collectively are still fairly rare. Put another way, even in founder 
populations like Newfoundland, the vast majority of mutant autosomal recessive alleles 
exist in healthy carriers rather than in affected individuals. 
We have shown that children with strongly genetic diseases collectively use more 
hospital resources than those with less genetic conditions. Children with strongly genetic 
diseases (group 1) had an average length of stay that was twice as long as those admitted 
with minimally genetic conditions (8.01 vs. 3.99 days). This was consistent with the 
McCandless et al. 2004 study. Moreover, we determined that children in the strongly 
genetic group had 1.8-fold more surgeries when corrected for age, compared with those 
in the moderately and minimally genetic groups. Finally when corrected for age, group 1 
children had 3.8-fold more cumulative hospital days than those in the minimally genetic 
group. 
Because of the strength of our length of stay (LOS) data, we used multivariate regression 
to examine the impact of the genetic content of an admission on LOS. We ran three 
regression analyses, but the genetic content of the admission explained no more than 
4.5% of the variance in LOS, compared with 34% of the variance which was explained 
by the admitting diagnosis. Nevertheless, we determined that children with teratogenic 
exposures (IC diagnoses) and those with single-gene disorders (IB) were at the highest 
risk for prolonged hospitalization(> 7 days). 
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When we analyzed referral rates for genetic consultation, the largest referral deficits 
occurred for the high heritability birth defects (only one-third referred) and for certain 
high heritability complex diseases including autism and unexplained mental retardation 
(again only one-third referred). During the 14-month study period, 3,281 unique 
hospitalizations generated 365 genetic consultations and we calculated that an additional 
129 children should have been referred. Fifteen percent of children in the unique data set 
had a diagnosis which is presently an indication for genetic consultation. The existing 
provincial medical genetics service would have difficulty coping with these additional 
assessments (about 110 extra children annually). Moreover, we estimated that if these 
same 3,281 children were to be hospitalized ten years from now, an additional 24% 
would require complex disease genetic testing which will probably be ordered by 
physicians who are not geneticists. 
In summary, we have determined that children with strongly and moderately genetic 
diseases are responsible for about 113 of pediatric admissions. The proportion of children 
with chromosomal and Mendelian diseases was comparable to earlier studies from more 
admixed populations, and the proportion of hospitalized Newfoundland children with 
birth defects was in fact lower. Compared to these earlier studies, children with 
multifactorial diseases (excluding birth defects) accounted for a larger fraction of our 
separations, and this may reflect increased disease prevalence related to Newfoundland's 
unique genetic architecture and/or to particular environmental factors acting on a 
genetically vulnerable background. Finally, we have shown that children with wholly 
genetic diseases (who account for about 8.3% of all admissions) use disproportionately 
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large amounts of inpatient hospital resources, and this information should be incorporated 
into future healthcare work force planning. 
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Appendix A -Diseases within the 11 genetic content categories (IA-IV) 
Category lA: Chromosomal disorders 







Ring chromosome mosaicism 
Category m: Single-gene disorders 
Arginosuccinate deficiency 
Arthrogryposis 




Cataracts (autosomal dominant) 
Citrullinemia 
Cleidocranial dysplasia 
Congenital adrenal hyperplasia (CAH) 






Factor V Leiden 









1 E.g. Angelman/Prader Willi syndrome, 22q 11.2 microdeletion, Williams syndrome. 
2 With mutant gene identified or with Mendelian family history. 
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Appendix A -Diseases within the 11 genetic content categories (lA-IV) 
Category m: Single-gene disorders (continued) 
1-cell disease (mucolipidosis type II) 
Ivemark syndrome (AR) 
Kiabbesleukodystrophy 
Lebers hereditary optic neuropathy 
Lesch-Nyhan syndrome 
Marfan syndrome 
Medium chain acyl CoA dehdrogenase (MCAD) deficiency 
Metachromatic leukodystrophy (MLD) 
Multiple endocrine neoplasia type 1 (MEN1) 
Mitochondrial myopathy 
Nemaline myopathy 
Neurofibromatosis type 1 (NF1) 







Protein C deficiency 





Severe combined immunodeficiency syndrome (SCIDS) 




Category IC: Teratogens 
Accutane embryopathy 
Diabetic embryopathy 
Fetal alcohol spectrum disorder (F ASD) 
Category ID: Genetic syndromes without identified gene and/or genetic 
mechanisim 
Goldenhar Syndrome (Hemifacial Microsomia) 
Kabuki syndrome 
V ACTERL association 
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Appendix A -Diseases within the 11 genetic content categories (IA-IV) 
Category IE: Probable unidentified genetic syndrome 
Examples: 
Child with unexplained developmental delay and dysmorphic facial features. 
Child with unexplained developmental delay and birth defects. 
Congenital myopathy (no muscle biopsy). 
Category IIA: Multifactorial birth defect with known recurrence risk to 
siblings (as per Harper 2001): 





Congenital heart disease 
Congenital hip dysplasia 
Craniosynostosis 
Cryptorchidism 










Neural tube defect 
Ossicular fusion 




3 Congenital hearing loss not meeting the IB criteria and without obvious environmental 
cause (e.g. prematurity). 
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Appendix A -Diseases within the 11 genetic content categories (IA-IV) 
Category Iffi: Birth defect with low recurrence risk to siblings 
(as per Harper, 2001) 







Cervical thymic cyst 









Leg length discrepancy 
Miscellaneous external ear malformations (including ear sinus) 
Multicystic dysplastic kidney 
Omphalocele 
Pilonidal sinus 
Posterior urethral valves 





Syrinx of spinal cord 
Tarsal coalition 
Tracheoespohageal fistula (TEF) 
Urachal remnant 
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Appendix A -Diseases within the 11 genetic content categories (IA-IV) 
Category IllA: Diseases with known genetic predisposition 





Attention deficit disorder/ Attention deficit hyperactivity disorder 
Autism spectrum disorder 
Cataract- not congenital 
Celiac disease 
Cervical and lumbar disc degeneration 
Conduct disorder 
Depression (childhood onset) 
Diabetes- Type 1 
Graves disease 
Hypothyroidism (including congenital) 
Inflammatory bowel disease (Crohns disease or ulcerative colitis) 
Juvenile rheumatoid arthritis 






Seizure disorders (febrile or afebrile)4 
Systemic lupus erythematousus (SLE) 
Tourette syndrome 
Vesicoureteric reflux (includes hydronephrosis due to reflux) 
4 Excludes first seizure which is classified as IIIB. 
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Appendix A -Diseases within the 11 genetic content categories (!A-IV) 
Cate~:orv IllB: Diseases with multiple known causes, sometimes genetic 
[including those with heritability (h2) < 50% or lambda s < 10] 
Allergies (environmental) 
Anemia 
Anomalies of dental arch 
Angioedema (sporadic) 
Anxiety disorders (panic disorder) 
Arrhythmias 
Atopic dermatitis (eczema) 
Blindness 
Cancer 




Diabetes - type II 
Diabetes gestational 
Disseminated intravascular coagulation (DIC) 
Encopresis 
Eosinophilic cystitis 
Failure to thrive (FIT) 
Gastroeosophageal reflux 




Hypertension, pregnancy induced 
Hypopituitarism 
Hypotonia 







Patent ductus arteriosus (not requiring surgery) 





5 Hearing loss not meeting the IB or IIA criteria. 
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Appendix A -Diseases within the 11 genetic content categories (lA-IV) 
Serwn sickness 
Wolf-Parkinson-White syndrome 
Cate~::ory IV- Acquired disease with low or no genetic contribution 
Bums 
Trauma 
Infection (e.g. pneumonia, infectious gastroenteritis) 
Chemotherapy-related complications 
Category V- No disease 
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Appendix B - ANCOV A 
Case Mixed Group (CMG) Codes 
Table A-1: Numbers of patients from unique admission dataset of3,281 patients 
belonging to each of the 20 most common Case Mixed Group (CMG) codes. 
20 most common CMG's Number of unique 
(code number) patients 
Seizures & headache (22) 99 
Mastoid procedures (85) 41 
External & middle ear procedures (90) 35 
Myringotomy (92) 44 
Tonsillectomy & adenoidectomy 374 
procedures (93) 
Influenza ( 1 04) 40 
Simple Pneumonia & pleurisy (143) 152 
Tracheobronchitis (145) 148 
Asthma (146) 140 
Simple Appendectomy (262) 38 
Esophagitis, gastroenteritis & Misc. 311 
digestive disease (294) 
Cellulitis ( 44 7) 32 
Diabetes ( 483) 54 
Major urinary tract procedures (504) 27 
Lower urinary tract infection (529) 33 
Upper extremity procedure for trauma 37 
(670) 
Other cranial injuries (695) 40 
Viral illness (757) 37 
Fever of unknown origin (761) 40 
Disruptive behavior disorders (786) 37 
Other CMG codes 1,522 
Total 3,281 
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Appendix C-1-Reanalysis of Day and Holmes (1973) data 
Day and Holmes 1973- Reanalysis of the frequency of genetic disease for 200 
pediatric admissions using the present study's genetic content categories 
Chromosomal disorders (our category lA) -no admissions 
Mendelian diseases (our category IB)- 8 admissions (4%) 
Environmental (our category IV) - 92 admissions ( 46%) -no diagnoses specified 
Table C-1: Number and diagnoses of patients from Day and Holmes 1973 study 
belonging to our genetic content categories IIA, JIB, IliA and !JIB 
Current study category Current study Current study Current study 
IIA: category liB: category lliA: category ITIB: 
(Diagnosis- number of (Diagnosis- number of (Diagnosis- number of (Diagnosis- number 
patients) patients) patients) of patients) 
NTD - 1 Urinary tract abnormality Asthma - 4 Hemia - 9 
Encephalocoele - I 
- 36 Psoriasis - I Cerebral palsy - 3 
Congenital heart disease - I Thyroglossal duct cyst - I Diabetes type I - 2 Wilms tumor - 3 
Pyloric stenosis - 3 Hemangioma- 1 Seizures- I Peripheral vasomotor 
Cong. dislocated hip - 1 Cystic hygroma - 2 Migraine - 3 instability - I 
Cleft palate - 1 Aneurismal bone cyst - 1 Parry-Rhomberg Chondromalacia - 1 
Cryptorchism -1 Agenesis left lung - 1 syndrome-! Chronic renal disease -
Ectopic anus - 1 Congenital 1 
encephalopathy - 1 
Tota122 (11 %) Tota143 (21.5%) Totall (8.5%) Total18 (9%) 
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Appendix C-2- Reanalysis of Hallet a/. 1978 data 
Hallet aL 1978- Reanalysis of the frequency of genetic disease for 4,115 admissions 
using the present study's genetic content categories 
Chromosomal (our study category lA) = 26 patients (0.6%) 
Mendelian (our study category ffi) = 162 patients (3.9%) 
Teratogen (our study category IC) = 11 patients (0.27%) 
Multiple anomalies suggestive of a genetic syndrome (IE)= 10 patients (0.24%) 
There were no diagnoses identified from Hall's diagnoses lists which would have been 
classified in the present study as ID (syndromes of unknown genetic etiology). 
IIA (high heritability birth defects) = 421 (10.2%), as shown in table A-3 below: 
Table C-2: Number and diagnoses of patients from Hall eta/. 1978 belonging to our 
genetic content category IIA (high heritability birth defects). 
Hall's category Diagnosis Frequency 
(number of patients) 
IIA - multifactorial established Cleft lip +/- palate 51 
Congenital heart malformation 162 
(no specific diagnoses given) 
Congenital dislocated hip 47 
Meningomyelocoele 44 
Club feet 20 
Hirschsprung disease 15 
Pyloric stenosis 14 
liB -presumed multifactorial Hydrocephalus 18 
III -developmental anomalies Cryptorchidism 25 
Hypospadias 25 
Total belonging to present 
study cate2ory IIA 421 
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Appendix C-2- Reanalysis of Hallet al. 1978 data 
Table C-3: Number and diagnoses of patients from Hall et al. 1978 belonging to our 
genetic content category JIB (low heritability birth defects). 
Hall's category Diagnosis Frequency 
_(number of patients) 
Ill -developmental anomalies Genitourinary anomalies 48 
(renal) 
Genitourinary anomalies 18 
(other gential excluding 
cryptorchidism & hypospadias) 
Other genitourinary anomalies 43 
Eye (including esotropia) 65 
Gastrointentinal anomalies 41 
(including TE fistula and 
imperforate anus) 
Skeletal (including limb 41 
abnormalities) 
Head and neck (including ear 40 
anomalies) 
Skin (including hemangiomas) 33 
CNS anomalies 15 
Miscellaneous 37 
Total belonging to present 381 
study category liB (9.3% of her dataset) 
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Appendix C-2 -Reanalysis of Hallet a/. 1978 data 
Table C-4: Number and diagnoses of patients from Hallet a/. 1978 belonging to our 
genetic content category IliA (high heritability multifactorial diseases excluding birth 
defects). 
Hall's category Diagnosis Frequency 
(number of patients) 
IIA - multifactorial established Allergy (including asthma) 157 
Diabetes type I 50 
lib -presumed multifactorial Seizures 137 
Scoliosis 26 
Mental retardation 24 
Others including migraine, 28 
RA, ulcerative colitis 
IV -familial Collagen vascular disorders 19 
Total belonging to present 441 
study category IliA (10.7% of her 
dataset) 
Table C-5: Number and diagnoses of patients from Hall eta/. 1978 belonging to our 
genetic content category !JIB (low heritability multifactorial diseases excluding birth 
defects). 
Hall's category Diagnosis Frequency 
(number of patients) 
IIA - multifactorial established Duodenal ulcer 4 
Hypertension 2 
lib - presumed multifactorial Cerebral palsy 99 
III -developmental anomalies Hernias 118 
IV -familial Cancers and tumors 230 
Renal disorders 108 
Prematurity 45 
Orthopedic disorders 41 
Hematologic 33 
RDS 12 
Newborn jaundice 10 
Aborted SIDS 8 
Miscellaneous 37 
Total belonging to present 747 
study category lliB (18.2%) 
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Appendix C-2- Reanalysis of Hallet a/. 1978 data 
Table C-6: Number and diagnoses of patients from Hallet al. 1978 belonging to our 
genetic content category IV (acquired disease with low or no genetic contribution). 
Hall's category Diagnosis Frequency 
(number of patients) 
V - non-genetic Infectious diseases 1,194 
Trauma 349 
Ingestions 80 
GI symptoms 68 
Burns 48 
Deficiency states 36 
Appendicitis 32 
Iatrogenic or post-operative 29 
complications 
Miscellaneous 51 
Total belonging to present 1,887 
study category IV ( 45.9% of her 
dataset) 
Healthy child (our genetic content category V) = 29 patients (0.7%) 
Table C-7: Summary of the number of patients from Hallet al. 1978 belonging to our 11 
genetic content categories. 
Present Number of Frequency (0/o) 
study patients in 
Cate2ory Hall et al. dataset 
IA 26 0.63 
IB 162 3.9 
IC 11 0.27 
ID - -
IE 10 0.24 
IIA 421 10.2 
liB 381 9.3 
IliA 441 10.7 
IIIB 747 18.2 
IV 1887 45.9 
v 29 0.70 
TOTAL 4,115 -100 
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Appendix C-3: 
Comparison of Categories from McCandless et al. 2004 to present study 
1. McCandless category lA = chromosomal and single gene disorders; 622 cases or 
10.8% oftheir dataset. This corresponds to categories lA, IB, ID and IE of present 
study (i.e. 8.4% of our consecutive separation dataset) 
2. McCandless category IB ("multifactorial I polygenic"): 823 cases or 14.5% of their 
dataset. All the McCandless IB diagnoses are included in our category II A (high 
heritability birth defect), except the following which we categorized as IliA: 
depression; seizures; celiac disease; scoliosis. 
3. McCandless category IC ('heterogeneous causes often genetic"): 495 cases or 8.6% 
of their dataset. We would have categorized these individual diagnoses as a mixture 
of categories IIA, liB, IliA, IIIB, ID and IE as shown below in table C-8: 
Table C-8: Diagnoses of patients from McCandless category IC belonging to our genetic 
content categories 1/A, JIB, 1/IA, !JIB, ID and IE. 
McCandless IC McCandless IC McCandless IC McCandless IC McCandless McCandless 
diagnoses diagnoses diagnoses diagnoses IC diagnoses IC diagnoses 
classified as classified as classified as classified as classified as classified as 
IIA in present liB in present IliA in present IIIB in present ID in present IE in present 
study study study study study study 
Congential Atresia large bowel; Adolescent kyphosis; ALTE; Oculoauriculo Arthrogryposis 
nystagmus; Arteriovenous Alopecia; Endometriosis ; Vertebral 
Congenital cataracts; malformation; Aortic aneurysm; ESRD; spectrum; 
Craniosynostosis; Bicornuate uterus; Autism; m; VACTERL 
Hearing loss•; Bone cysts; Developmental Membranopro !if. association 
Microcephaly; Branchial cleft cyst; Delay; Glomerulonephritis; 
Congenital heart Hypothyroidism; Myoglobinuria; 
block; Migraine; Nasal sinus polyp; 
Congenital Mental retardation; Osteochondroma; 
hydrometroculpous; Obesity; Ovarian cysts; 
Congenital Recurrent joint Pes plannus; 
diaphragmatic hernia; dislocation Recurrent 
Hydronephrosis; pneumothorax; 
Laryngotracheomalcia Recurrent vomiting; 
Mandible hypoplasia; Retinal detachment; 
Microcolon; Supraventricular 
Pectus excavatum; tachycardia; 







*We classified hearing loss as IB if the child had a Mendelian family history or had a 
mutation in one of the deafness genes. Hearing loss was classified IIA if it was congenital 
without obvious environmental cause and did not meet the IB criteria. Otherwise hearing 
loss was categorized as IIIB. 
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Appendix C-3: 
Comparison of Categories from McCandless et a/. 2004 to present study 
4. McCandless category IIA ("malformations of unknown etiology") contained 48 cases 
or 0.84% of their total separations. It partially overlapped with our category liB (low 
heritability birth defects) as shown below in table C-9. 
Table C-9 Diagnoses of patients from McCandless category IIA belonging to our genetic 
content categories JIB, IIA and !D. 
McCandless IIA diagnoses McCandless IIA diagnoses McCandless IIA diagnoses 
classified as lffi in present classified as IIA in present classified as ID in present 
study (i.e. agreement) study (i.e. disagreement) study (i.e. disagreement) 
Bladder extrophy Branchial cleft sinus Sturge-Weber syndrome 
Hydrocoele Chiari I malformation 
Meckel diverticulum 
5. McCandless category JIB ("teratogens") completely agreed with our category IC. 
Their data set contained 19 cases (0.33% of their total hospitalizations). Our dataset 
contained 8 cases or 0.2% of our total hospitalizations. 
6. McCandless category III (acquired disorder with genetic predisposition) contained 
2,096 cases (36.5% of total cases). It was a mixture of our categories IliA and IIIB 
(higher and lower heritability multifactorial diseases, excluding birth defects) as 
shown below in table C-10. 
Table C-10: Diagnoses of patients from McCandless category III belonging to our 
genetic content categories IIIA and !JIB. 
McCandless III diagnoses McCandless III diagnoses 
classified as IliA in classified as IIIB in 
present study present study 
Asthma; ALL; 
Crohns disease; Benign bone tumor; 
Graves disease; CML; 
Inflammatory bowel disease; Exostosis; 
Type I diabetes; Germ cell tumor; 
Juvenile rheumatoid arthritis; Hodgkins lymphoma; 





Milk protein intolerance; 
SLE; 
Suicide; 
Ulcerative colitis 
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